

1 Combined protein and transcript single cell RNA sequencing reveals cardiovascular disease and  
2 HIV signatures

3 Jenifer Vallejo, Ryosuke Saigusa (equal contribution) et al.

4 Short title: Human CVD signatures by single cell RNA-Seq

5

6

7 Corresponding Author

8 Klaus Ley, MD

9 La Jolla Institute for Immunology

10 9420 Athena Circle

11 La Jolla, CA 92037, USA

12 (858) 752-6661 (tel)

13 (858) 752-6985 (fax)

14 [klaus@lji.org](mailto:klaus@lji.org)

15

16 Total word count: 12257

17

18

19

20

1 **Abstract**

2 **Background.** HIV-infected people have an increased risk of atherosclerosis-based  
3 cardiovascular disease (CVD), even when the HIV virus is fully controlled. Both chronic HIV  
4 infection and CVD are chronic inflammatory diseases. The interaction between these two  
5 diseases is not well understood.

6 **Methods.** The Women's Interagency HIV Study (WIHS) collected peripheral blood mononuclear  
7 cells (PBMCs) and data on subclinical CVD defined by carotid artery ultrasound from HIV-infected  
8 women. We interrogated 32 PBMC samples using combined protein and transcript panel single  
9 cell (sc) RNA sequencing of women without HIV or CVD, with HIV only, with HIV and CVD, and  
10 with HIV and CVD treated with cholesterol-lowering drugs. Expression of 40 surface markers  
11 enabled detailed analysis of all major cell types, resolving 58 clusters in almost 42,000 single  
12 cells.

13 **Results.** Many clusters including 5 of 8 classical monocyte clusters showed significantly different  
14 gene expression between the groups of participants, revealing the inflammatory signatures of  
15 HIV, CVD and their interactions. Genes highly upregulated by CVD included CCL3, CCL4 and IL-  
16 32, whereas CXCL2 and 3 were more highly upregulated by HIV. Many genes were synergistically  
17 upregulated by HIV and CVD, but others were antagonistically regulated, revealing that the gene  
18 signature in people with HIV and CVD is not simply the sum of the HIV and CVD signatures.  
19 Elevated expression of most inflammatory genes was reversed by cholesterol control (statin  
20 treatment). The cell numbers in 3 of 5 intermediate monocyte subsets, 1 of 14 CD8 T cell subsets,  
21 1 of 6 B cell subsets and 1 of 6 NK cell subsets showed significant changes with HIV or CVD.

22 **Conclusions.** We conclude that HIV and CVD show interactive inflammatory signatures including  
23 chemokines and cytokines that are improved by cholesterol-lowering drugs.

24

25 Keywords: CVD, HIV, scRNA-seq, transcriptomes, surface markers, antibodies, PBMC, human,  
26 cholesterol-lowering drugs.

27

## 1 **Introduction**

2 Most people living with HIV, including the Women's Interagency HIV Study (WIHS) participants,  
3 are on antiretroviral therapy (ART), leading to low or undetectable HIV viral loads<sup>1</sup>. Nevertheless,  
4 low-level systemic inflammation remains measurable.<sup>2</sup> Chronic inflammation is thought to drive  
5 morbidity and mortality in people living with HIV, much of it from sequelae of cardiovascular  
6 disease (CVD).<sup>3,4</sup> Cardiovascular risk in people living with HIV is elevated ~3-fold compared to  
7 uninfected controls.<sup>5,6</sup> Within the next 10 years, it is expected that 78% of people living with HIV  
8 will be diagnosed with CVD.<sup>7,8</sup> How persistent inflammation in chronic HIV infection drives CVD  
9 is not known. Predicting the prognosis or monitoring the efficacy of therapies remains challenging.

10 Prior studies characterized peripheral blood mononuclear cells (PBMCs) in HIV-infected  
11 people and uninfected controls using flow cytometry or mass cytometry. Other than the well-  
12 known loss of CD4 T cells in HIV infection<sup>9</sup> and their rebound with ART,<sup>10</sup> changes were noted in  
13 monocytes and natural killer (NK) cells.<sup>11</sup> Among people living with HIV, those with CVD showed  
14 a loss of CXCR4 expression in nonclassical monocytes (NCM).<sup>12</sup> Other studies reported an  
15 association between monocytes and coronary artery calcium progression in people living with  
16 HIV<sup>13</sup>, persistent activation of classical monocytes (CM),<sup>14,15</sup> changes in NK cells,<sup>11,16–22</sup> CD8 T  
17 cells<sup>23–26</sup> and B cells.<sup>27–32</sup>

18 WIHS is an ongoing multi-center, prospective, observational cohort study of over 4,000  
19 women with or at risk of HIV infection that was initiated in 1994. Almost all WIHS participants with  
20 HIV are on ART. PBMCs were cryopreserved and shipped on liquid N<sub>2</sub>, following strict standard  
21 operating procedures that ensured preservation of cell surface phenotype, viability and  
22 transcriptomes.<sup>33</sup> PBMCs can be analyzed without mechanical or enzymatic dissociation, which  
23 are known to alter cell surface markers and transcriptomes.<sup>34</sup> PBMC are attractive for single cell  
24 RNA sequencing (scRNA-Seq) studies, because they are available in many clinical studies of  
25 specific populations with defined diseases and outcomes. The participants sampled for the  
26 present study were part of a substudy nested within the WIHS,<sup>35,36</sup> which provided detailed

1 information on subclinical atherosclerosis. Participants underwent high-resolution B-mode carotid  
2 artery ultrasound to image six locations in the right carotid artery.<sup>37</sup>

3 scRNA-Seq has been applied to human PBMCs in diseases including cancers,<sup>38–41</sup>  
4 inflammatory bowel disease<sup>42,43</sup> and autoimmune disease<sup>44,45</sup>. One study reported the effect of  
5 acute HIV infection on PBMC transcriptomes<sup>46</sup>. No single cell studies of PBMCs of people living  
6 with chronic HIV infection and CVD have been reported.

7 Here, we report transcriptomes and cell surface phenotypes of almost 42,000 PBMCs from  
8 31 participants of the WIHS study at unprecedented resolution. We used the targeted scRNA-Seq  
9 BD Rhapsody platform<sup>47,48</sup> that simultaneously provides surface phenotype (40 mAbs) and  
10 transcriptomes (485 immune and inflammatory transcripts) in the same cells. We compared non-  
11 HIV non-CVD with HIV+ women (HIV effect), HIV+ women with and without subclinical  
12 cardiovascular disease as assessed by carotid ultrasound (CVD effect) and the effect of treatment  
13 with cholesterol-lowering drugs (statin effect). Hundreds of genes in tens of clusters were  
14 significantly differentially expressed between the disease groups. Six of 58 resolved PBMC  
15 clusters showed significant changes in cell proportions specific for HIV or CVD.

16

17

18

## 1 **Results**

### 2 **Population and cells.**

3 The 32 WHS participants studied were aged 47-62, all (ex)smokers, most African American or  
4 Hispanic. Matched groups of 8 women each were selected for subclinical CVD and HIV status:  
5 CVD-HIV- (non-CVD non-HIV); CVD-HIV+ (living with HIV); CVD+HIV+statin- (living with HIV,  
6 evidence of CVD); CVD+HIV+statin+ (living with HIV, evidence of CVD, treated with cholesterol-  
7 lowering drugs) (**Table S1**). PBMC tubes were shipped from the central repository on liquid N<sub>2</sub>,  
8 thawed and processed according to standard operating procedures. Cell viability was 88±5%  
9 (**Table S2**). To avoid batch effects, all cells were hash-tagged for multiplexing, with 4 samples run  
10 per 250,000-well plate (total of 8 plates). The pooled cells were labeled with 40 titrated  
11 oligonucleotide-tagged mAbs (**Table S3**). After quality controls and three-stage doublet removal,  
12 41,611 single cell transcriptomes from 31 WHS participants (one sample was lost in hash  
13 tagging) were successfully analyzed (**Table S4**). An overview of the experimental design and  
14 workflow is shown in **Figure S1**.

15

### 16 **Surface marker-based cell identification.**

17 In combined protein and transcript panel single cell sequencing, just like in CITE-Seq,<sup>49</sup> REAP-  
18 Seq<sup>50</sup> or flow cytometry, non-specific binding contributes to the antibody signal, in part, because  
19 Fc block is not complete.<sup>51,52</sup> The type and number of Fc receptors varies among cell types,  
20 causing different levels of background for the same antibody in different cell types.<sup>53-56</sup> Additional  
21 background is caused by unbound oligonucleotide-tagged antibody remaining in the nanowell that  
22 will be amplified and sequenced.<sup>48</sup> To account for all sources of background, we gated based on  
23 biaxial plots of mutually exclusive markers. This yielded thresholds for all 40 markers used (**Table**  
24 **S5**). After thresholding, we used Boolean gating on surface markers to readily identify known cell  
25 types to the satisfaction of experts in the field. An alternative to surface marker-based cell calling  
26 is integrated analysis by surface markers and transcripts using Seurat.<sup>57,58</sup> (**Figure S2**).

## 1 **Correlation between gene and cell surface marker expression.**

2 In immunology, surface markers are widely used to define and distinguish cell types.<sup>59–62</sup> The  
3 correlation between cell surface protein and mRNA expression is weak in immune cells.<sup>63</sup>  
4 Therefore, scRNA-Seq without surface phenotype information has led to much frustration in the  
5 field, because the expression of many genes encoding well-known surface markers remains  
6 undetected in scRNA-Seq.<sup>59,64,65</sup> It is still difficult to call cell types based on gene expression data  
7 alone, which emphasizes the need for cell surface phenotypes in addition to transcriptomes. Here,  
8 we correlated gene expression with cell surface expression for 41 pairs of genes and proteins  
9 **(Table S6)**. For most markers, we confirm weak correlations<sup>63</sup>, which illustrates the value of  
10 monitoring cell surface phenotype in scRNA-Seq.

11

## 12 **Major cell types.**

13 T, B, NK cells and monocytes were identified by 8 antibody markers using biaxial gating,  
14 corresponding to established gating schemes for human PBMCs.<sup>66–68</sup> CD3 and CD19 expression  
15 are mutually exclusive and specific for T and B cells, respectively **(Figure S3)**. Thus, we identified  
16 CD4 **(Figure S4A)** and CD8 T cells **(Figure S4B)**, classical, nonclassical and intermediate  
17 monocytes **(Figure S4C)**, B cells **(Figure S4D)**, and natural killer (NK) cells **(Figure S4E)**.<sup>69–71</sup>

18


## 19 **Subclustering.**

20 Each major cell type **(Figure 1, center)** was subclustered by all expressed surface markers **(Table**  
21 **S7)** using UMAP and Louvain<sup>72</sup> clustering **(Figure 1)**. Gates were overlaid and used in all  
22 subsequent UMAP figures (cell numbers in **Table S8**). Violin plots of surface marker distribution  
23 of each cluster in **figure S5**.

24

25

26



**Figure 1**

1  
2 **Figure 1. Antibody-based UMAP clustering of major cell types.** The major known cell types were UMAP-Louvain-  
3 clustered by CD3, CD19, CD14, CD16 and CD56 surface expression (central panel). Then, each major known cell type  
4 was UMAP-Louvain-clustered by all non-negative surface markers (see table S7 for list). **(A) CD4 T cells** formed 16  
5 clusters, cluster numbers indicated; **(B) CD8 T cells** formed 14 clusters; **(C) Classical monocytes (CM)** formed 8, **(D)**  
6 **Intermediate monocytes (INT)** 5 and **(E) Nonclassical monocytes (NCM)** 3 clusters. **(F) B cells** and **(G) NK cells**  
7 formed 6 clusters each.

8  
9 **Among CD4 T cells (Figure 2A),** CD2, the ligand for CD48 and CD58, was expressed in almost  
10 all cells, as expected. The high affinity IL2 receptor IL2RA (CD25) was expressed in about a third  
11 of the CD4 T cells and was strikingly high in cluster 13, which was also low for IL7 receptor  
12 (CD127), defining regulatory T cells (Tregs).<sup>73,74</sup> CD45RA and RO were mutually exclusive,

1 separating naive and antigen-experienced CD4 T cells. CXCR3 (CD183) identifies T-helper-1  
2 (Th1) cells in human PBMCs<sup>75</sup> and was highly expressed in clusters 6, 14 and 16. Cluster 14 co-  
3 expressed CXCR5 (CD185) with CXCR3. Cluster 7 expressed CXCR5 as the only chemokine  
4 receptor, suggesting it may contain follicular helper (TFH) T cells. Based on surface marker  
5 information, all CD4 T cell clusters were called (**Figure 3A**).

6  
7 **CD8 T cells.** All CD8 T cells expressed CD2 (**Figure 2B**). Cluster 3 exclusively expressed CD9  
8 and CD36, identifying these cells as NK-like CD8 cells.<sup>76,77</sup> Clusters 7 and 13 were identified as  
9 NK-like T cells with a CD45RA<sup>+</sup> terminally differentiated memory (EMRA) phenotype. Based on  
10 these markers, all CD8 T cell clusters were called (**Figure 3B**).

11  
12 **Monocytes (Figure 2C).** As expected, all **classical monocytes (CM)** were CD11b<sup>+</sup> (**Figure 2C**).  
13 There were gradients of CD9<sup>78</sup>, CD69, CD137, CD142 (tissue factor) and CD163 (hemoglobin-  
14 haptoglobin receptor) expression. The scavenger receptor CD36 and the antigen presentation co-  
15 receptor CD86 were expressed in all classical monocytes. As expected, the chemokine receptor  
16 CCR2 was expressed in all classical monocytes. Based on these markers, 5 of the 8 classical  
17 monocyte subsets were called (**Figure 2C**) and related to subsets described by mass cytometry.<sup>78</sup>


18 **Intermediate CD14<sup>+</sup>CD16<sup>+</sup> monocytes (INT)** have been considered pro-inflammatory by  
19 several investigators<sup>79–83</sup> and are known to be increased in people with HIV<sup>84,85</sup> and with  
20 CVD.<sup>82,86,87</sup> All intermediate monocytes highly expressed the inflammation-induced costimulatory  
21 molecule CD86 (**Figure 2C**). Cluster INT3 highly expressed CD142 (tissue factor), which has  
22 previously been implicated in people living with HIV.<sup>14</sup> Since subsets of intermediate monocytes  
23 have not been described before, we propose a provisional naming suggestion (**Figure 3C**).

24 **Nonclassical monocytes (NCM)** are considered anti-inflammatory.<sup>88</sup> In this study, they formed  
25 3 clusters (**Figure 2C**). Strikingly, expression of CD9 and CD36 was limited to cluster 3,




- 1 suggesting that this cluster corresponds to the previously described CD9+CD36+ NCM.<sup>78</sup> CD11c,
- 2 CD74<sup>78</sup>, CD86 and CD141 were expressed in all NCMs (Figure 3C).

### A. CD4 T cells



### B. CD8 T cells



### C. Monocytes






Figure 2

## D. B cells



## E. NK cells



**Figure 2**

1  
2 **Figure 2. Cell surface marker expression.** The expression level of each of the 40 antibody markers was color-coded  
3 from dark blue (=0, not expressed) to red (highest expression, log2 scale, as per color bar in each panel). Rainbow  
4 plots projected on UMAP gates of each cell type. Selected surface markers shown on top of each plot; all others in  
5 Figure S3. Cluster outlines as defined in figure 2. (A) CD4 T cells; (B) CD8 T cells; (C) Classical (CM), intermediate  
6 (INT) and non-classical (NCM) monocytes; (D) B cells and (E) NK cells. Violin plots of surface marker distribution  
7 of each cluster in figure S5. Cluster calling in figure 3.  
8


9  
10 **B cells.** As expected, CD20 and CD74 (HLA-DR) were expressed in all B cells. (Figure 2D).  
11 CD27, IgM and IgD are used to identify naïve B cells (CD27-IgM+IgD+).<sup>27,89</sup> Clusters 1, 3 and 4  
12 were negative for CD27 with high transcript expression for IgM and IgD, consistent with naïve B  
13 cells. Clusters 3 and 4 expressed CCR6, a subset found in HIV+ subjects<sup>30</sup>. B cell cluster 2  
14 expressed CD25, which is a known marker for activation for B cell proliferation and exhaustion,<sup>90,91</sup>  
15 and CD27, identifying cluster 2 as a likely activated memory B cell. Cluster 5 had high CD11c  
16 levels, known to increase in HIV-infected patients,<sup>32</sup> and expressed some CXCR3 and CCR6, but

1 was CD27<sup>low</sup>. These features together with moderate expression of CD22 transcript suggest that  
2 cluster 5 may contain CD11c+ pathologic B cells.<sup>32</sup> (**Figure 3D**).

3

4 **NK cells.** Most NK cells were mature (CD56<sup>dim</sup>/CD16+), as expected. Cluster 3 also contained  
5 immature (CD56<sup>bright</sup>CD16-) NK cells. The CD56<sup>low</sup>CD16- cells (clusters 4 and 5) expressed CD2  
6 and CD45RA. Cluster 5 was CD56-CD16<sup>high</sup>, an NK cell subset known to be elevated in chronic  
7 HIV infection.<sup>69,70</sup> (**Figure 2E, S4, Figure 3E**).

## A. CD4 T cells



## B. CD8 T cells






Figure 3


### C. Monocytes



### D. B cells



### E. NK cells



**Figure 3**

1  
 2 **Figure 3. Heatmaps of antibody expression (log2 scale) in each main cell type: A) CD4 T cell, B) CD8 T cell, C)**  
 3 **Monocytes, D) B cell and E) NK cells.** Immunophenotypes at the bottom. Blank means uncalled. Abbreviations: EM;  
 4 **effector memory, EMRA; terminally differentiated effector memory; CM, Classical Monocyte; INT, Intermediate**  
 5 **Monocyte; NCM, Nonclassical Monocyte.**


1 **Transcriptomes.**

2 Next, we analyzed the transcriptomes of each single cell (**Excel Table S1**). We tested gene  
3 expression of each cluster against all other clusters in each major cell type (**Figure 4**), using  
4 Seurat to report the data as log2 fold-change (logFC) and percent of cells expressing each gene.  
5 Significant overexpression of *GNLY*, *GZMA*, *GZMH*, *NKG7* and *FGFBP2* together with the surface  
6 phenotype (**Figure 3A**) confirmed **CD4 T cell** cluster 1 as effector memory (EM). We found two  
7 clusters of EMRA cells that expressed CD25RA with quite different transcriptomes: cluster 8  
8 EMRA overexpressed *CHI3L2* and cluster 9 EMRA cells overexpressed *GNLY*, *GZMA*, *GZMB*,  
9 *GZMH*, *NKG7*, *FGFBP2*, *PRF1*, *HOPX*, *FCN1*, the chemokine *CCL3*, the Th1 cytokine *IFNG* and  
10 the Th1 transcription factor *TBX21* (**Figure 4A**).


11  
12 **Among CD8 T cells (Figure 4B)**, CD45RA+ cluster 2 was naive based on significant  
13 overexpression of *CCR7*, *SELL* and *IL7R*. Cluster 7 was confirmed to contain CD56+ EMRA (NK-  
14 like EMRA) based on significant overexpression of *KLRF1*. Cluster 8 (CD11b+CD56+EMRA)  
15 significantly overexpressed *S100A9* and *FCN1*. Clusters 12 and 13 had NK-like phenotypes,  
16 based on significant overexpression of *FCGR3A*, *GZMB* and *KLRB1*.

17  
18 **In monocytes**, CM5 overexpressed *CD1C*, *CLEC10A* and *FCER1A*. Among intermediate  
19 monocytes, cluster 3 significantly overexpressed *S100A12*, *CD14*, *CD163*, *CLEC4E*, *THBS1*,  
20 *MGST1*, *RNASE2* and 6. Nonclassical monocytes, B and NK cells showed little differential gene  
21 expression. Exact p-values of differential gene expression in all major cell types are in **Table S9**.

### A. CD4 T cells



### B. CD8 T cells



### C. Monocytes




Figure 4

1

2 **Figure 4. Significantly differentially expressed genes of cells in each cluster.** Expression of 485 transcripts was  
 3 determined by targeted amplification (BD Rhapsody system). Significant genes defined as adjusted  $p < 0.05$  and  $\log_2$   
 4 fold change  $> 1$ . Dot plot: fraction of cells in cluster expressing each gene shown by size of circle and level of expression  
 5 shown from white (=0) to dark blue (=max,  $\log_2$  scale). Red bars indicate genes that were significantly higher in each

1 cluster compared to all other clusters of the parent cell type. **(A) CD4 T cells, (B) CD8 T cells and (C) monocytes**  
2 (Classical monocytes; CM, Intermediate monocytes; INT, Non-classical monocytes; NCM).  
3

#### 4 **Ingenuity Pathway Analysis.**

5 To identify pathways enriched in the different PBMC clusters, we used Ingenuity pathway  
6 analysis<sup>92</sup>. **(Figure S6, Table 1)** The pathway “communication between innate and adaptive  
7 immune cells” was very highly enriched in B cells and several monocyte subsets, with p values  
8 below  $10^{-10}$ . The main genes contributing to this enrichment were the chemokines *CCL5* and  
9 *CCL8*, the co-activators *CD83* and *CD86*, the Fcε receptor *FCER1G*, major histocompatibility  
10 complex-II (*HLA-DRA*), the cytokines interferon-γ (*IFNG*), IL-15 (*IL15*), and IL-1β (*IL1B*), the Toll-  
11 like receptors *TLR2* and *TLR8* and the TNF superfamily members *TNF* and *APRIL (TNFSF13)*.  
12 Th1 and Th2 pathways were highly enriched in several T cell subsets. This enrichment was driven  
13 by the TCR signaling subunits *CD3D* and *CD3E*, the co-receptor *CD4*, the co-activator *CD86*, the  
14 chemokine receptor *CXCR4*, the adhesion molecule *ICAM1*, interferon-γ (*IFNG*) and its receptor  
15 (*IFNGR1*), the IL-2 receptor subunit *IL2RB*, β2 integrins (*ITGB2*), the killer lectin receptor *KLRC1*  
16 and *KLRD1* and the transcription factors *RUNX3*, *STAT4* and *TBX21*. The atherosclerosis  
17 signaling pathway was enriched in the monocyte clusters INT3, INT5 and CM1. The genes driving  
18 this enrichment were the scavenger receptor *CD36*, lysozyme (*LYZ*), the adhesion molecules  
19 *PSGL-1 (SELPLG)*, *ICAM-1* and integrins α4 (*ITGA4*) and β2 (*ITGB2*), *TNF*, the known CVD-  
20 causative cytokine IL-1β (*IL1B*), the chemokine IL-8 (*CXCL8*), the chemokine receptor *CXCR4*  
21 and the pro-atherogenic cytokine interferon-γ (*IFNG*). More significantly enriched pathways are  
22 shown in **Table 1**.

23

24

25

26

27



1 **Table 1. Significantly enriched pathways.**

Antigen Presentation Pathway	<b>CD8T5, CM5, CD4T13, INT4, CD8T14, CM1, CD8T3, INT3, CD8T2, CD4T9, CM3, CD8T9, CD8T6, CD4T10, CD4T12, B2, CD4T4, CD8T7, CD4T2, CD8T10, B1, CD4T7, CD8T11</b>
Atherosclerosis Signaling	<b>INT5, CM1, INT3, CD4T9, CD4T6, CD8T14, CD4T12, CD8T6, B5, CM5, CD8T2, CD8T7, CM3, B3, INT4, CD8T9, B6, CM7, CD4T8, INT2, CD8T12</b>
B Cell Development	<b>B2, CD4T13, CD8T5, B1, INT4, CD8T3, B6, INT3, CM5, CD8T2, B3, B4, CD8T14, CM1, INT5, CM2, CD4T9, CD4T12, CD8T9, CD8T6, CD4T6, CD8T10, INT1, CM3, CM4, CD8T13, CD4T10</b>
Chemokine Signaling	<b>CD8T5, CD8T2, CD4T14, CD4T12, CD8T9, CD8T6, CD8T14, CD8T1, CM5, CD4T1, CD4T8, CD4T9, CD8T7, CD4T2, CD4T6</b>
Communication between Innate and Adaptive Immune Cells	<b>B4, B6, B2, CD8T6, B3, B5, B1, CD4T12, CD8T9, CM5, CD4T9, CD8T2, INT5, CD8T5, CM1, CD8T13, CM3, CD8T7, CD4T13, CD8T14, CD8T3, CD4T10, CD8T1, INT3, CD4T4, CD4T1, CD4T8, CD4T2, CM2, CD8T12, CD4T14, INT1</b>
Crosstalk between Dendritic Cells and Natural Killer Cells	<b>CD4T12, CD8T2, CD8T6, CD8T14, CD8T13, B6, CD8T9, B4, CD4T9, CD4T13, CD8T7, CD8T12, B5, CD4T2, CD8T3, CD8T1, CD8T5, CD4T4, CD4T8, B3, CM2, B2, CM1, CD4T10, INT3, CD4T1, CD4T16</b>
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells	<b>CD8T12, CD4T12, CD8T2, CD8T7, CD8T9, CD8T11, B2, CD4T13, CD8T14, CD8T3, CD8T1, CD4T9, CD8T6, CD4T16, CD8T8, B1, CD4T5</b>
Dendritic Cell Maturation	<b>B6, B5, CM5, B4, INT3, B2, CD4T13, CM1, B1, CD4T12, B3, INT4, INT5, CD8T5, CD8T6, CD4T4, CD4T15, CD4T8, CM3, CM2, CD8T2, CD4T2, CD8T14, CD8T9, CD8T3, CD8T1</b>
Fcy Receptor-mediated Phagocytosis in Macrophages and Monocytes	<b>INT5, CD8T12, CM4, CD8T13, CD8T2, CD8T1, INT3, B5, CD8T7, INT2, CD4T12, CD8T9, INT1</b>
Granulocyte Adhesion and Diapedesis	<b>CM3, CM5, CD4T12, INT5, INT3, CD8T6, CD8T2, CD8T9, CD4T9, CD8T7, CM1, CD8T12, CD8T5, CD4T8, CD4T6, CD8T14, CD8T13, CD8T3, CD4T14, CD8T1, CD4T4, B5, CD4T1, CD8T4, CD4T2, CD8T11, CD4T13, INT4, CM4, CD4T10, CM7</b>
IL-7 Signaling Pathway	<b>B5, CD8T2, CD8T5, CD8T14, CD8T13, CD4T10, CD8T10, CD4T9, CD8T7, CD8T12, B1, CD4T12, B3, CD8T11, CD8T9, CD8T6, B2, CD8T3, B6, CD8T1, CD4T4, CD4T1, CD4T2, CD4T6, CD4T14, CD4T3</b>
Interferon Signaling	<b>B3, B5, CD8T2, INT1, CM3, B4, CM4</b>
Natural Killer Cell Signaling	<b>CD8T12, CD8T13, CD8T2, INT5, CD4T12, CD8T7, CD4T2, CD8T14, CD4T10, CD8T9, CD8T6, CD4T8,</b>

	CD8T3, CD8T1, CD4T4, CD8T11, B2, CD4T13, CD8T5
Necroptosis Signaling Pathway	CD4T5, CD4T2, CM5, CD4T1
Phagosome Formation	<b>B5, CM5, B6, INT5, B1</b> , B2, CM4, CD8T12, B3, B4, CD4T12, CD8T14, CD8T13, INT3 CD4T6, CD8T7, INT2
T Cell Receptor Signaling	<b>CD8T2, CD8T12</b> , CD4T8, CD4T2, CD8T11, CD4T12, CD8T6, CD4T4, CD4T1, CD8T7
Th1 and Th2 Activation Pathway	<b>CD8T2, CD4T12, CD8T6, CD8T9, CD8T12, CD8T14, CD4T10, CD4T9, CD8T5, B2, CD4T8, CD4T2, CD8T13, CD8T3, B6, CD4T7, B5, CD4T13, CM5, CD4T1, CD8T7</b> , CM1, CD4T15, CD4T4, B3, INT4, CD4T16, CD4T14, CD4T3, INT3, B1, CM3, CM2, B4, CD8T11, INT5, CD8T1, CD4T6
Th1 Pathway	<b>CD8T2, CD4T12, CD8T6, CD8T9, CD4T10, CD8T12, CD4T9, CD8T14, CD8T3, CD8T5, CD4T7, CM1, CD8T13, CD4T15</b> , CM5, CD8T7, B2, CD4T13, INT4, CD4T16, B6, INT3 B5, CD4T1, CD4T8, CD4T2, CM3, CM2, B4, CD8T11, INT5, CD8T1, CD4T4
Th17 Activation Pathway	CM1, INT5, CD4T12
Th2 Pathway	<b>CD8T2, CD4T12, CD8T9, CD8T6, CD8T14, CD4T10, CD8T12, CD8T5, B2, CD4T8, CD4T9, CD4T2, CM5, CD4T1, CD4T13, CD8T3, B6</b> , CD4T4, B5, CD4T7, CD8T7, INT4, CM1, INT3, CD4T3, B1, CD4T15, CM3, CM2, B3, CD8T13, CD4T6
Toll-like Receptor Signaling	<b>CM5</b> , CM3, INT5, INT3, CD4T1, CD4T2, INT1
TREM1 Signaling	<b>CM5, CM1, CM3</b> , CM4, INT5, B6, B5, B4, CM2, CD8T13, INT3, CD4T9, CM7, CD4T12, CD4T3, CD8T2


1 All pathways shown were significantly enriched in the clusters indicated. **Bold: P<0.0001**,  
2 others p<0.05.

3

#### 4 **Gene expression changes by HIV, CVD and cholesterol control.**

5 Next, we reasoned that HIV, CVD and cholesterol control would be associated with specific gene  
6 expression changes. We focused non-HIV vs HIV+ (reflecting the HIV signature), HIV+ vs  
7 HIV+CVD+ (reflecting the CVD signature), and HIV+CVD+ vs HIV+CVD+ treated with LDL  
8 cholesterol-lowering drugs (reflecting the cholesterol control signature) (**Figure 5**). In a bulk RNA-  
9 Seq study, we found that statins had a strong effect on sorted classical monocyte  
10 transcriptomes.<sup>15</sup> In 27 of the 58 PBMC clusters, expression of hundreds of genes was  
11 significantly (adjusted p<0.05) regulated; 181 between women with and without HIV, 465 between

1 women with HIV and women with HIV and CVD, and 303 in women with HIV and CVD that  
2 received cholesterol-lowering drugs. We discovered by far the most regulated genes in classical  
3 monocytes: 98 in cluster 1, 88 in cluster 2 and 55 in cluster 3. The top 10 highly regulated genes  
4 for the main cell types are shown in **Table S10** and all the underlying gene expression data in  
5 **Excel table S2**. **Figure 5** shows the cell types with the most regulated genes; volcano plots for  
6 clusters with fewer genes are shown in **Figure S7**.



**Figure 5**




Figure 5

- 1
- 2 **Figure 5. Volcano plots comparing gene expression in single cells from WIHS participant types in each cluster.**
- 3 All 3 meaningful comparisons were calculated, but this figure is focused on HIV+CVD- vs HIV+CVD+, and HIV+CVD+ vs HIV+CVD+ with cholesterol medication; all clusters in which at least 10 genes were statistically significant. Colored
- 4

1 dots (HIV+CVD- yellow, HIV+CVD+ blue, and HIV+CVD+ with cholesterol medication red) indicate significantly  
2 differentiated expressed genes (FDR<0.05 and |log2FC|>2). 3 CD4 T and 7 CD8 T cell clusters, 5 CM and 1 each INT  
3 and B cell clusters met these criteria. Dashed line indicates adjusted p-value of 0.05. Additional volcano plots shown in  
4 Figure S7, full data set shown in Excel Table S2.  
5

6 **T cells.** In CD4T1, 2 and 8, IL-32 was highly significantly increased by CVD, which was reversed  
7 by cholesterol lowering in CD4T1 and 2 (**Figure 5, Table S11**). IL-32 is an inflammatory cytokine  
8 that is known to be important in CVD.<sup>93-95</sup> In CD4T2, L-selectin (*SELL*), PSGL-1 (*SELPLG*) and  
9 *CCR7* were also highly significantly increased in WIHS participants with HIV and CVD, and  
10 significantly corrected by cholesterol lowering (**Figure 5**). In addition to *SELL* and *SELPLG*,  
11 CD4T8 showed strong upregulation of TNFSF10 (*TRAIL*). In CD8T1 and 2, *IL32* was strongly  
12 induced in women with CVD and significantly corrected by cholesterol control. Other genes highly  
13 induced by CVD in CD8T1 included *CD52*, *TRAC* and *HOPX*. Several killer cell lectin receptors  
14 (*KLRC4*, *KLRD1*, *KLRG1*, *KLRK1*) were also significantly upregulated in CVD and restored to  
15 near-control by cholesterol-lowering drugs. In CD8T2, the activation marker CD69 was  
16 significantly downregulated by cholesterol-controlling drugs. In CD8T3, *CD52*, *CCL5*, *IL32* and  
17 *CD160* were all significantly upregulated by CVD. *CCL5* encodes the chemokine RANTES, known  
18 to be important in atherosclerosis.<sup>96</sup> In CD8T4, CVD significantly increased *IL32*, *TRAC*, *HOPX*,  
19 *CCL5* and the killer lectin receptors *KLRK1*, *KLRC4*, *KLRD1* (figure 5).

20  
21 **In classical monocyte** cluster 1, CVD strongly and significantly increased *CCL4*, *SLC2A3*, *SOD2*  
22 and *SELPLG*, all reversed by cholesterol control. In CM2, *TNF*, *DUSP1* and 2 were highly  
23 upregulated by CVD (**Figure 5**), as were TNFSF10 (*TRAIL*), TNFSF13 (*APRIL*) and TNFSF13B  
24 (*BAFF*). *BAFF* and *APRIL* are important B cell regulators.<sup>97,98</sup> In addition to *CCL3*, *CCL4* and  
25 *DUSP2*, *IL1B*, known to be highly relevant in atherosclerosis,<sup>99</sup> was highly upregulated in CM3 of  
26 HIV+CVD+ participants. The Toll-like receptor TLR2, which is known to be involved in  
27 atherosclerosis,<sup>100-102</sup> was upregulated by CVD in CM3. In **intermediate monocyte** cluster 3,

1 *CCL3*, *CCL4*, *TNF*, *IL1B* and *DUSP2* were upregulated by CVD and most were corrected by statin  
2 treatment.

3


#### 4 **Gene expression patterns in WIHS participants with HIV and CVD.**

5 Figure 5 showed that many genes were significantly upregulated by HIV and CVD and corrected  
6 by cholesterol control. We systematically explored such patterns of gene expression (**Figure 6**).  
7 The most common pattern, seen in 21 genes, was decreased expression in women with HIV,  
8 increased in CVD and corrected by cholesterol control (down-up-down). Twelve other genes  
9 showed increased expression in participants with HIV, further increased in participants that also  
10 had subclinical CVD, and then reduced in participants on cholesterol-lowering drugs (up-up-  
11 down). We found 3 genes that were significantly upregulated in participants with HIV, reduced in  
12 participants with CVD, and further reduced by cholesterol control (up-down-down). One gene,  
13 interferon- $\gamma$  receptor (*IFNGR1*) was reduced by HIV, even more reduced in presence of CVD, and  
14 further reduced cholesterol-lowering drug treatment (down-down-flat, **Figure 6**).


15 **The down-up-down pattern** was the most common in CD4 T cells (**Figure 6A**). The  
16 chemokine receptor *CCR7* and the adhesion molecules L-selectin (*SELL*) and PSGL-1 (*SELPG*),  
17 the inflammatory cytokine IL-32 (*IL32*) and the cytoskeleton modulator *CYTIP* all followed this  
18 pattern. In CD8 T cells (**Figure 6B**), *IL32*, *SELPLG*, the killer lectin receptors *KLRD1*, *KLRG1*,  
19 *KLRK1* and the interferon-responsive gene *IFITM2* all followed this pattern. In classical (**Figure**  
20 **6C**) and intermediate monocytes (**Figure 6D**), *TNF* showed the down-up-down behavior, as did  
21 *IL1B* in intermediate monocytes. In non-classical monocytes, *CCL4* and *CD52* were  
22 downregulated in participants with HIV, up in participants with CVD and corrected by cholesterol  
23 control (**Figure 6E**). In B cells, *CD74* and the BCR subunits *CD79A* and *CD79B* were down by  
24 HIV, up by CVD and corrected by cholesterol-lowering drugs (**Figure 6F**). Finally, this pattern was  
25 also seen for two Fc receptor genes in NK cells, *FCGR3A* and *FCER1G* (**Figure 6G**).

26

### A. CD4 T cells



### B. CD8 T cells



### C. Classical monocytes






Figure 6




### D. Intermediate monocytes




### E. Nonclassical monocytes



### F. B cells



### G. NK cells



**Figure 6**

1

2 **Figure 6. Gene expression patterns by HIV, CVD and cholesterol medication.** The log<sub>2</sub> normalized expression of  
 3 the genes listed above each panel shown as line graphs for each of the indicated cell types (average of all cells). Genes  
 4 selected by significant differential expression. All data shown as HIV-CVD-, HIV+CVD-, HIV+CVD+, HIV+CVD+ on  
 5 cholesterol medication (statin), from left to right. The line graph patterns were categorized as up-up-down (white


1 background), down-up-down (blue background), up-down-down (yellow background), and down-down-flat (green  
2 background).  
3

4 **The up-up-down pattern** was the most common in classical monocytes (**Figure 6C**),  
5 where the inflammatory chemokines CCL3, CCL4 and CCL20, the inflammatory cytokines IL1B  
6 and IL6, and the water channel AQP9 followed this pattern. In intermediate monocytes, CCL3 and  
7 CCL4 also followed this pattern, as did membrane-bound IgM (*IGHM*) in B cells (**Figure 6F**). *IL32*  
8 and *KLRC3* in NK cells were upregulated in women with HIV, further increased by CVD and  
9 downregulated by cholesterol-lowering drugs (**Figure 6G**).

10 **The up-down-down pattern** was less common. It was characteristic of CXCL  
11 chemokines in classical monocytes (**Figure 6C**), specifically the neutrophil-attracting chemokines  
12 CXCL2 and CXCL3 as well as the CXCR6 ligand CXCL16, which is also a scavenger receptor.<sup>103–  
13 <sup>105</sup> The underlying raw data for figure 6 is presented as **Excel Table S3**.</sup>

#### 14 15 **PBMC subsets with significant differences of abundance.**

16 Finally, we asked whether HIV and CVD affected the abundance (cell number) of PBMC subsets.  
17 As expected,<sup>46,106</sup> we found that CD4 T cells were significantly reduced in people living with HIV.  
18 We compared the proportions (cell percentages) for each of the 58 clusters using log odds ratio  
19 followed by ANOVA and Tukey's multiple comparison test. We compared non-HIV vs HIV+  
20 (reflecting the HIV effect), HIV+ vs HIV+CVD+ (reflecting the CVD effect), and HIV+CVD+ vs  
21 HIV+CVD+ treated with LDL cholesterol-lowering drugs (reflecting the cholesterol control effect)  
22 (**Figure 7**). Strikingly, three subsets of **intermediate monocytes (Figure 7A)** showed  
23 significantly different proportions. INT2 (IL7R-) and INT3 (TF<sup>hi</sup>) were significantly elevated in  
24 WIHS participants living with HIV and then drastically reduced in those that also had subclinical  
25 CVD. Cholesterol control significantly restored these cells. INT4 had an opposite pattern: These  
26 CD163- cells disappeared in WIHS participants living with HIV, reappeared in those that also had  
27 subclinical CVD, and were slightly reduced by cholesterol control.



**Figure 7**

1

2 **Figure 7. Cell proportions in women with HIV, CVD, both or neither.** HIV-CVD- (green), HIV+CVD- (yellow),

3 HIV+CVD+ (blue), HIV+CVD+ on cholesterol medication (statin, red), from left to right. 8 samples per group except 7

4 for HIV+CVD+. Proportions of cells in each cluster calculated as percent of the parent cell type as indicated in the title

5 of each panel. Clusters with significant differences (\*,  $p < 0.05$ , \*\*,  $P < 0.01$ , \*\*\*,  $p < 0.001$ ) in cell proportions (by log odds

6 ratio) are shown with individual data points representing the standard error of the mean (SEM). Violin plots below show

7 expression of all 40 cell surface markers (Log<sub>2</sub> scale). Cluster description is as in figure 2 and 3.

8

9 Among **CD8 T cells**, CD8T5 (CD38+HLA-DR+) (**Figure 7B**) were rare in HIV-CVD- WIHS

10 participants, but increased in disease, becoming significant in HIV+CVD+ treated with cholesterol-

1 lowering medications. Among **B cells**, activated memory B2 cells (**Figure 7C**) were severely  
2 lower in all diseased WIHS participants, whether they lived with HIV or also had subclinical CVD.  
3 Among **NK cells**, CD11b+ mature NK cells (cluster 2) (**Figure 7D**) were reduced in women with  
4 HIV with or without CVD.

5

## 6 **Discussion**

7 Here, we used combined protein and transcript panel scRNA-Seq to identify 58 clusters of PBMCs  
8 in 31 participants of the WIHS study. The most diversity was in CD4 T cells (16 clusters),  
9 monocytes (16 clusters) and CD8 T cells (14 clusters). B cells and NK cells were resolved into 6  
10 clusters each. The most salient findings were that many inflammatory genes were significantly  
11 increased in WIHS participants with CVD, and many of these genes were downregulated in  
12 participants on cholesterol-lowering drugs. Six clusters showed significantly different abundance  
13 of cells in the four groups of participants, three of them intermediate monocyte subsets, which  
14 underscores the extraordinary importance of this cell type in chronic HIV infection<sup>107,108</sup> and  
15 CVD<sup>109,110</sup>. Intermediate monocyte numbers have previously been found to be increased in  
16 peripheral artery occlusive disease<sup>111</sup> and significantly predicted cardiovascular events.<sup>82,112</sup> Here,  
17 we discovered 5 subsets of intermediate monocytes. Intermediate monocyte subsets have not  
18 been described before.

19 INT1, the largest cluster, express the defining intermediate monocytes markers CD14 and  
20 CD16. They also share CD11b, CD11c, CD9, CD36, CD38, CD56, CD69, CD83, IL-3RA, IL6R,  
21 CD137, CD141, CD142 (tissue factor), CXCR4 and CD74 (HLA-DR) with all other intermediate  
22 monocytes. We found no single positive marker that was specific for INT1 and thus refrained from  
23 naming this cluster. INT2 uniquely lacks IL-7R (CD127, table 1); we propose to call these cells IL-  
24 7R<sup>-</sup> intermediate monocytes. INT2 cells also lack CXCR3. INT3 (CD142<sup>hi</sup>) express tissue factor,  
25 the initiator of coagulation, even more strongly than INT2. Tissue factor expression has previously  
26 been found in intermediate monocytes<sup>110</sup> and was increased in HIV+ subjects<sup>14</sup>. The proportion

1 of INT2 and INT3 is increased in women living with HIV. Intermediate monocytes are considered  
2 pro-atherogenic,<sup>79</sup> and tissue factor expression provides a plausible reason for this. In INT2 and  
3 INT3, the inflammatory chemokines CCL3 and CCL4 and the known pro-atherogenic cytokine IL-  
4 1 $\beta$  are significantly upregulated in participants with CVD. This is fully reversed in subjects  
5 receiving cholesterol-lowering medication. INT4 uniquely lack expression of CD163, the receptor  
6 for hemoglobin-haptoglobin complexes. Thus, we call INT4 CD163<sup>-</sup> intermediate monocytes.  
7 INT5, called CTLA4+CXCR3<sup>hi</sup>, uniquely express CTLA4 (CD152) and highly express CXCR3.  
8 Since intermediate monocyte subsets are currently not defined in mice, more discovery research  
9 in mice is needed to address the function of these intermediate monocyte subsets.

10 In peripheral blood, we confirmed that CD4 T cells counts were significantly lower in  
11 people living with HIV. In many CD4 T cell clusters, *IL32* mRNA expression was prominently  
12 increased by CVD. IL-32 is a 27 kDa cytokine expressed in T cells, NK cells and monocytes that  
13 is secreted after apoptosis. It is an inflammatory cytokine that drives IL-1 $\beta$ ,<sup>99</sup> TNF, IL-6 and IL-8  
14 expression,<sup>94,95</sup> cytokines that are known to be important in CVD. IL-32 activates the leukocyte  
15 surface protease PR3, which in turn triggers the G-protein coupled receptor PAR2 and is known  
16 to be important in viral infections.<sup>113</sup> We found IL-32 highly expressed in most T and NK cell  
17 clusters. IL-32 expression appears to be specific for CVD and responds to cholesterol lowering.  
18 Prospective studies in larger cohorts will be needed to determine whether *IL32* mRNA is a useful  
19 biomarker.

20 One of the most striking findings of our study was that many pro-inflammatory cytokines  
21 and chemokines that were increased in CVD in many cell types were corrected by treatment with  
22 cholesterol-lowering drugs (mostly statins, see **Table S1**). Statins are known to lower several  
23 inflammatory biomarkers.<sup>114</sup> Rosuvastatin is known to decrease the progression of subclinical  
24 atherosclerosis in HIV+ subjects,<sup>115</sup> which was previously attributed to cholesterol lowering. A  
25 large ongoing clinical trial, the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE),  
26 is testing the effects of pitavastatin on CAD and inflammatory biomarkers.<sup>116</sup> Our data suggest

1 that, in addition to LDL cholesterol lowering, statin treatment has significant anti-inflammatory  
2 benefits. This has been shown in earlier studies<sup>117</sup> and our findings greatly extend this to many  
3 human blood cell types.

4         When analyzing gene expression differences among the participant types, we found two  
5 common patterns. The up with HIV-up with CVD-down with statin (up-up-down) pattern of gene  
6 expression can perhaps be called the expected pattern, since both HIV and CVD are pro-  
7 inflammatory, and since statins are known to be anti-inflammatory.<sup>117</sup> However, we also found  
8 many genes that followed the down-up-down pattern, which means that their expression was  
9 decreased by HIV, increased by CVD and corrected by cholesterol control. Thus, not all  
10 inflammatory genes are regulated in the same direction by HIV and CVD, suggesting that for  
11 some genes, HIV and CVD are synergistic, for others antagonistic. Consistently across cell types,  
12 controlling LDL cholesterol showed an anti-inflammatory gene signature.

13         In this study, CVD was assessed by carotid ultrasound. Thus, some of the markers  
14 discovered here may be expected to be better indicators for stroke than CVD elsewhere. There  
15 is overlap between stroke, myocardial infarction and peripheral artery disease risk, but the  
16 correlation is not perfect.<sup>118</sup> This discovery study will encourage prospective epidemiological  
17 studies to address which PBMC subsets are best suited as clinical biomarkers to stratify risk and  
18 guide treatment in subjects with CVD or coronary artery disease or peripheral artery disease.

19         In the WIHS study, participants were exceptionally well phenotyped, attending semi-  
20 annual follow-up visits, during which they underwent detailed examinations, specimen collection,  
21 and structured interviews assessing health behaviors, medical history, and medication use.<sup>119</sup>  
22 These significant strengths are balanced by limitations of the present study. We don't know  
23 whether the same changes in PBMCs would be observed in non-HIV populations. The multiethnic  
24 study of atherosclerosis (MESA<sup>120</sup>) is an example of such a cohort. The current findings also need  
25 to be extended to men (the current data is based on women) and Caucasians (the current data is  
26 based on mostly African American and Hispanic women). Studies of CVD in non-smokers are

1 also needed (the current data is based on smokers and ex-smokers), and the age range needs  
2 to be broadened.

3 Six PBMC clusters showed significantly changed proportions in response to HIV, CVD,  
4 cholesterol control, or combinations. This finding is directly translatable, because these cells are  
5 defined by surface markers and thus can, in future validation studies, be identified by standard  
6 flow cytometry (**Table S12**), a method that is routinely used in monitoring HIV+ people.<sup>121</sup>

7 CD8 T cell numbers in HIV+ males are associated with increased risk of acute myocardial  
8 infarction.<sup>24</sup> The effect of cholesterol-lowering drugs on CD8 T cell activation is unclear.<sup>25,26</sup> Major  
9 clinical trials have shown a potential benefit (reduced CVD risk) in HIV-infected populations  
10 treated with statins,<sup>116</sup> but the specific cell types affected were not known prior to the present  
11 study. Here, we show that the TEMRA clusters CD8T1, 3, 7 and 9, naïve CD8 T cells (CD8T2),  
12 effector memory CD8 T cells (CD8T4) and CD38+ CD8 T cells (CD8T5) all show significant  
13 decreases in inflammatory gene expression in subjects treated with cholesterol-lowering drugs.

14 It is known that HIV disease leads to impaired B cell and antibody responses.<sup>122</sup> Our study  
15 identified B cell cluster 2 with high expression of CD25, a known marker for B cell proliferation,  
16 activation and exhaustion,<sup>91</sup> suggesting that premature exhaustion of these B cells could be linked  
17 to a decreased antibody response in HIV+ individuals.<sup>91</sup> CD11c+ B cells are increased in number  
18 in HIV infected patients, which agrees with our observation in B cell cluster 5. A recent study  
19 showed that a putative human B-1 cell may be linked to atherosclerosis.<sup>28</sup> Specifically, the  
20 percentage of circulating CD20+CD27+CD43+ cells was directly correlated with levels of IgM to  
21 oxidation-specific epitopes on low density lipoprotein (LDL) and inversely correlated with coronary  
22 artery plaque volume, especially in cells with high expression of CXCR4.<sup>28</sup> Here, we found  
23 significantly decreased CXCR4 surface expression in several B cell clusters in subjects with CVD,  
24 supporting the idea that CXCR4 on some B cells may have atheroprotective roles. Among NK  
25 cells, we found the proportion of cells in cluster 2 to be significantly reduced in HIV+CVD+  
26 participants that were on cholesterol-lowering drugs. CD56<sup>bright</sup> NK cells are known to accumulate

1 in human atherosclerotic lesions, possibly contributing to plaque instability.<sup>123</sup> Symptomatic  
2 carotid atherosclerotic plaques are often infiltrated by NK cells,<sup>123</sup> but the exact subset was not  
3 investigated and their mechanistic role remains unknown.

4 In conclusion, we present the first study of scRNA-Seq with cell surface phenotype  
5 assessment in the same cells in people living with HIV, with and without documented CVD.  
6 Beyond the translational and clinical utility of our findings, the identification of 58 distinct clusters  
7 of CD4 and CD8 T cells, monocytes, B cells and NK cells helps to gain a deeper understanding  
8 of PBMCs, a rich and readily accessible source of biological and clinical information. The  
9 discovery of subsets of intermediate monocytes calls for identifying such subsets in model  
10 organisms to test their function in vivo. Many inflammatory genes are upregulated by HIV, CVD  
11 or both, and in most cases corrected by statin treatment.

12

13

14

15

16

17



1 **Methods**

2 **Study characteristics and sample selection.** The Women’s Interagency HIV Study (WIHS) was  
3 initiated in 1994 at six (now expanded to ten) U.S. locations.<sup>36,37</sup> It is an ongoing prospective study  
4 of over 4,000 women with or at risk of HIV infection. Recruitment in the WIHS occurred in four  
5 phases (1994-1995, 2001-2002, 2010-2012, and 2013-2015) from HIV primary care clinics,  
6 hospital-based programs, community outreach and support groups. Briefly, the WIHS involves  
7 semi-annual follow-up visits, during which participants undergo similar detailed examinations,  
8 specimen collection, and structured interviews assessing health behaviors, medical history, and  
9 medication use. All participants provided informed consent, and each site’s Institutional Review  
10 Board approved the studies.

11  
12 All participants in the current analysis were part of a vascular substudy nested within the  
13 WIHS.<sup>124,125</sup> The baseline visit for the vascular substudy occurred between 2004 and 2006, and a  
14 follow-up visit occurred on average seven years later. Participants underwent high-resolution B-  
15 mode carotid artery ultrasound to image six locations in the right carotid artery: the near and far  
16 walls of the common carotid artery, carotid bifurcation, and internal carotid artery. A standardized  
17 protocol was used at all sites,<sup>35,126</sup> and measurements of carotid artery focal plaque, a marker of  
18 subclinical atherosclerosis, were obtained at a centralized reading center (U. of Southern  
19 California). Subclinical CVD (sCVD) was defined based on the presence of one or more carotid  
20 artery lesions.<sup>35</sup>

21  
22 From the initial 1,865 participants in the WIHS vascular substudy, 32 participants were selected  
23 for scRNA-seq analysis. Because we were interested in the joint relationships of HIV infection  
24 and sCVD with surface marker and RNA expression by different cell subtypes, we used a two-by-  
25 two factorial design based on HIV, CVD and cholesterol treatment (mostly statins). CVD was  
26 defined as presence of carotid artery focal plaque at either vascular substudy visit to define four

1 groups of eight participants each: HIV-, HIV+CVD-, HIV+CVD+, HIV+CVD+ treated with  
2 cholesterol-lowering drugs. HIV infection status was ascertained by enzyme-linked  
3 immunosorbent assay (ELISA) and confirmed by Western blot. CVD participants either had one  
4 or more plaques at each vascular substudy visit, or more than one plaque at a single visit. Non-  
5 CVD participants with self-reported coronary heart disease or current lipid-lowering therapy use  
6 were excluded. Participants were formed in quartets matched by race/ethnicity (except one  
7 quartet), age ( $\pm$  5 years) at the baseline vascular substudy (except one quartet where the age  
8 difference was more but all the women were post-menopausal), visit number, smoking history,  
9 and date of specimen collection (within 1 year).

10

11 Demographic, clinical, and laboratory variables were assessed from the same study visit using  
12 standardized protocols. **Table S1** shows characteristics of the study population. The median age  
13 at the baseline study visit was 55 years, and 96% of participants were either of black race or  
14 Hispanic ethnicity. Most (86%) reported a history of smoking. Substance use was highly  
15 prevalent, with 43% of HIV+ and 50% of HIV- participants reporting either a history of injection  
16 drug use; current use of crack, cocaine, or heroin; or alcohol use ( $\geq$ 14 drinks per week). Among  
17 HIV+ participants, over 80% reported use of HAART at the time PBMCs were obtained, and 59%  
18 reported an undetectable HIV-1 RNA level. The median CD4+ T-cell count was 585 cells/ $\mu$ L (IQR  
19 382-816) in HIV+ women without sCVD and 535 cells/ $\mu$ L (IQR 265-792) in HIV+ women with  
20 sCVD.

21

22 **Preparation of PBMC samples for CITE-seq.** To avoid batch effects, sixteen samples each  
23 were processed on the same day. PBMC tubes were thawed in a 37°C water bath and tubes filled  
24 with 8 mL of complete RPMI-1640 solution (**Table S13**; cRPMI-1640 contains Human Serum  
25 Albumin, HEPES, Sodium pyruvate, MEM-NEAA, Penicillin-Streptomycin, GlutaMax and

1   Mercaptoethanol). The tubes were centrifuged at 400 xg for 5 minutes and pellets resuspended  
2   in cold staining buffer (SB: 2 % fetal bovine serum (FBS) in phosphate-buffered saline (PBS)).  
3   All reagents, manufacturers and catalogue numbers are listed in **Table S13**. Manual cell counting  
4   was performed by diluting cell concentration to achieve 100-400 cells per hemocytometer count.  
5   Cells were aliquoted to a count of 1 million cells each and incubated on ice with Fc Block (BD,  
6   **Table S13**) at a 1:20 dilution, centrifuged at 400 xg for 5 minutes, resuspended in 180  $\mu$ L of SB  
7   and transferred to their respective sample Multiplexing Kit tubes (BD). The cells were incubated  
8   for 20 minutes at room temperature, transferred to 5 mL polystyrene tubes, washed with 3 mL SB  
9   and centrifuged at 400 xg for 5 minutes. The addition of 2 mL of SB to the tubes and centrifugation  
10   was repeated 2 more times for a total of 3 washes. The cells were resuspended in 400  $\mu$ L of SB  
11   and 2  $\mu$ L of DRAQ7 and Calcein AM were added to each tube. The viability and cell count of each  
12   tube was determined using the BD Rhapsody Scanner (Scanner) (**Table S2**). Tube contents were  
13   pooled in equal proportions with total cell counts not to exceed 1 million cells. The tubes were  
14   then centrifuged at 400 xg for 5 minutes and resuspended in a cocktail of 40 AbSeq antibodies (2  
15    $\mu$ L each and 20  $\mu$ L of SB) on ice for 30-60 minutes per manufacturer's recommendations. The  
16   tubes were then washed with 2 mL of SB followed by centrifugation at 400 xg for 5 minutes. This  
17   was repeated two more times for a total of 3 washes. The cells were then counted again using  
18   the Scanner.

19  
20   **Library preparation.** Cells were loaded at 800-1000 cells/ $\mu$ L into the primed plate. The plate was  
21   primed and then loaded and unloaded per the User Guide described by BD when using a Scanner.  
22   The lysis buffer that was collected was removed by having the beads isolated with a magnet and  
23   the supernatant removed. Reverse Transcription was performed at 37°C on a thermomixer at  
24   1200 rpm for 20 minutes. Exonuclease I was then incubated at 37°C on a thermomixer at 1200  
25   rpm for 30 minutes and then immediately placed on a heat block at 80°C for 20 minutes. The tube

1 was placed on ice followed by supernatant removal while beads were on a magnet. The beads  
2 were resuspended in Bead Resuspension solution (provided in BD kit). Then, the tubes were  
3 stored in 4°C until further processing. Per BD's protocol, the reagents for PCR1 including the BD  
4 Human Immune Response Panel and our custom panel of ~100 genes were added to the beads.  
5 Next samples were aliquoted into four 0.2 mL strip PCR tubes and incubated for 10 cycles  
6 according to BD's protocol for PCR1. A double size selection was performed using AMPure XPre  
7 beads at a ratio of 0.7X (RNA tube). The supernatant was transferred to a new tube and an  
8 additional 100 µL of AMPure XP beads were added (sample tags and antibodies). The RNA tube  
9 was washed twice with 500 µL of 80 % ethanol. 550 µL of supernatant were removed from the  
10 antibody tube followed by two washes with 500 µL of 80 % ethanol. The cDNA was eluted off the  
11 beads using 30 µL of BD elution buffer and then transferred to a 1.5mL tube.

12

13 **Pre-sequencing quality control (QC).** A QC/ quantification check was performed on the tube  
14 containing AbSeq and Sample Tags using Agilent TapeStation high sensitivity D1000 screentape.  
15 5 µL from each tube (mRNA and Ab/ST) was then added to their respective tubes containing the  
16 reagents for PCR2. mRNA had the reagents required for amplifying the Human Immune  
17 Response Panel and the Custom panel, while the Sample Tags had the reagents required for  
18 amplifying them specifically. Each tube had 12 cycles of PCR performed according to BD' User  
19 Guide. Each tube was then cleaned with AMPure XP beads with the following ratios 0.8X for  
20 mRNA and 1.2X for ST. Two 200 µL washes were performed during the clean-up using 80 %  
21 ethanol per sample. The cDNA was eluted off using BD elution buffer. A QC/ quantification check  
22 was performed using Agilent TapeStation high sensitivity D1000 screen tape and Qubit double  
23 stranded high sensitivity DNA test kit. The mRNA was then diluted, if necessary, to a  
24 concentration of 1.2-2.7 ng/µL and the Ab/ST tube as well as the Sample Tag library from PCR2  
25 were diluted, if needed, to a concentration of 0.5-1.1 ng/µL. From each sample 3 µL were added

1 to a volume of 47  $\mu$ L of reagents for PCR3 as described by BD's User Guide following the protocol  
2 and number of cycles listed, except for AbSeq, which had 9 cycles of PCR performed as described  
3 by previous optimization. The three libraries were then cleaned with AMPure XP beads at the  
4 following ratios: mRNA 0.7X AbSeq and Sample Tag 0.8X. Samples were washed twice with 200  
5  $\mu$ L of 80 % ethanol. The cDNA was eluted off the beads using BD's elution buffer. Then a final  
6 QC and quantification check was performed using TapeStation and Qubit kits and reagents.

7

8 **Sequencing.** The samples were pooled and sequenced to the following nominal depth  
9 recommended by BD: AbSeq:  $n \times 1000$  reads per cell, where  $n$  is the plexity of AbSeq used;  
10 mRNA: 20,000 reads per cell; Sample Tags: 600 reads per cell. A total of 60,600 reads per cell  
11 were desired for sequencing on the NovaSeq. The samples and specifications for pooling and  
12 sequencing depth, along with number of cells loaded onto each plate was optimized for S1 and  
13 S2 100 cycle kits (Illumina) with the configuration of 67x8x50 bp. Once sequencing was complete,  
14 a FASTA file was generated by BD as a reference for our AbSeq and genes we targeted with  
15 these assays. The FASTA file and FASTQ files generated by the NovaSeq were uploaded to  
16 Seven Bridged Genomics pipeline, where the data was filter in matrices and csv files. This  
17 analysis generated draft transcriptomes and surface phenotypes of 54,078 cells (496 genes, 40  
18 antibodies). 11 genes were not expressed, i.e. had exactly 0 total reads in all cells combined.  
19 These genes were removed, leaving 485 genes for analysis.

20

21 **Doublet Removal.** Based on the 4 sample tags used per plate, 8,359 doublets were removed.  
22 The remaining 45,719 cells were analyzed using the Doublet Finder package on R  
23 (<https://github.com/chris-mcginnis-ucsf/DoubletFinder>) with the default doublet formation rate  
24 (7.5%). This removed another 3,322 doublets, leaving 42,397 Cells. Finally, we removed all cells  
25 that had less than 128 ( $2^7$ ) antibody molecules sequenced. This removed 786 noisy cells, resulting

1 in 41,611 cell transcriptomes. All antibody data were CLR (centered log-ratio) normalized and  
2 converted to log2 scale. All transcripts were normalized by total UMIs in each cell and scaled up  
3 to 1000.

4

5 **Identifying Major Cell Types by Biaxial Gating.** To identify the major known cell types, we used  
6 antibodies to CD3, CD19, CD4, CD8, CD14, CD16 and CD56. Cell type definitions:

- 7 • B cells: CD19+ and CD3-
- 8 • T cells: CD19- and CD3+ as T cells. (To find CD4T and CD8T further ahead in the  
9 analysis)
- 10 • CD4 T cells: CD4+ and CD8- T cells
- 11 • CD 8 T cells: CD8+ and CD4- T cells
- 12 • Monocytes and NK cells from CD19-CD3- (non-B non-T cells)
- 13 • CM: CD14+CD16- (non-B non-T cells)
- 14 • INT: CD14+CD16+ (non-B non-T cells)
- 15 • NCM: CD14-CD16+CD56- (non-B non-T cells)
- 16 • NK: CD4- CD56+ CD14- CD20- CD123- CD206- (non-B non-T cells)

17

18 As is standard in the NK cell field,<sup>127</sup> the CD16- immature NK cells were gated to a higher level of  
19 CD56 as shown in figure S3. The mature NK cells were CD19-CD3-CD16+CD56+. One  
20 CD16+CD56- cluster was also identified as NK cells. This resulted in 2919 B cells, 11,045 CD4 T  
21 cells, 12,843 CD8 T cells, 5,145 CM, 1009 INT, 475 NCM and 1,843 NK cells.

22

23 **Thresholding.** Each antibody threshold (**Table S5**) was obtained by determining its expression  
24 in a known negative cell. To identify the thresholds, biaxial plots of mutually exclusive markers  
25 were used to best separate the positive populations from the noise. In combined protein and

1 transcript panel single cell sequencing, non-specific background staining is caused by incomplete  
2 Fc block and oligonucleotide-tagged antibody being trapped in the nanowell.<sup>49</sup>

3

4 **Clustering.** Clustering was performed using UMAP (Uniform Manifold Approximation and  
5 Projection) and Louvain clustering.<sup>72</sup> UMAP is a manifold learning technique for dimensionality  
6 reduction. It is based on the neighborhood graphs, which captures the local relationship in the  
7 data. UMAP is able to maintain local structure and also preserve global distances in the reduced  
8 dimension, i.e the cells that are similar in the high dimension remain close-by in the 2 dimensions  
9 and the cells that different are apart in the 2 dimensions. There are a few parameters that define  
10 the dimensionality reduction when using UMAP; 1) N\_neighbours: This is used to create the  
11 neighborhood graph. It controls how the UMAP balances the local and the global structure. It  
12 gives the size of the local neighborhood the algorithm looks at while trying to obtain the lower  
13 dimensional manifold. Larger values give a more global view while smaller values give more on  
14 local view. 2) n\_pcs: This gives the number of principal components of the data to consider while  
15 creating the neighborhood graph. 3) min\_dist: This parameter provides the minimum distance  
16 between embedded points. Smaller values result in more dense embedding while larger values  
17 result in a more spread-out embedding. 4) Spread: This parameter determines the scale at which  
18 the points are spread out. Together with min\_dist, it determines the closeness of points in the  
19 cluster. The clustering parameters used were: n\_neighbors = 100, n\_pcs = 50, min\_dist = 1,  
20 spread = 1, random state = 42. Louvain resolution was set at 0.8. Subclustering of each major  
21 cell type was based on all non-negative antibodies (**Table S7**).

22

23 **Cluster Assignment.** Louvain clusters produced 12 clusters with clearly bimodal expression of  
24 at least one cell surface marker. In CD4 T cell, 4 of the initial clusters were further divided based  
25 on the expression of CD11c, CD56, CD25, CD127, CXCR3 and CCR2. CD8 T cells had two  
26 clusters that were divided based on CD11c, CD16 and CXCR3 surface marker expression. One

1 cluster from classical monocytes and one cluster from intermediate monocytes were further  
2 divided based on CCR7 and CD152 expression, respectively. In non-classical monocytes, one  
3 cluster showed differential expression of CD36 and CD152 surface marker expression and was  
4 divided in two. In B cells, one cluster was split because it showed differential expression of CD25  
5 and CXCR3 within the cluster. Finally, two clusters from NK cells were split due to CD16, CD56  
6 and CD11c expression.

7

8 **Comparing Gene Expression among Participant Types.** To determine differential expression  
9 (DE) among the four types of participants, we use the Seurat package in R with no thresholds  
10 over avg\_logFC, minimum fraction of cells required in the two populations being compared,  
11 minimum number of cells and minimum number of cells expressing a feature in either group. We  
12 filtered for adjusted  $p < 0.05$  and compared HIV-, HIV+CVD-, HIV+CVD+ and HIV+CVD+ statin-  
13 treated. From this data, volcano plots were generated using ggplot2 and ggrepel packages in R,  
14 Axis were restricted to the range of (-2,2) on the x-axis and (0,20) on the y-axis. Genes outside  
15 these ranges were bounded to the corresponding limit of the axes.

16

17 **Comparing Cell Proportions.** To find changes in proportions, we identified the cell numbers for  
18 each participant in each cluster (**Table S4**). Statistical differences in cell proportions were  
19 calculated by log-odds ratio defined as  $p/(1-p)$  where  $p$  is the proportion of cells, followed by  
20 ANOVA and Tukey's multiple comparison test between the four groups. For clarity, the data is  
21 presented as percentage of cells.

22

23 **Correlation Analysis.** We correlated each antibody to its corresponding gene(s) using Spearman  
24 rank correlation and significance (R package). For each combination of gene-antibody, we  
25 discarded cells that had values below the corresponding threshold for that antibody as well as  
26 cells with zero counts for that gene. After this filter, any gene-antibody combination that had 10



1 cells or less was deemed insignificant. Finally, all non-significant ( $p$ -value  $> 0.05$ ) were designated  
2 a nominal value of zero as the Spearman rank correlation coefficient and we selected only those  
3 genes or antibodies that had at least one correlation whose coefficient  $\geq 0.25$  or whose  
4 coefficient  $\leq -0.25$ . All significant non-negative correlations are reported in **Table S6**.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1 **Authors**

2

3 Jenifer Vallejo,<sup>1#</sup> Ryosuke Saigusa,<sup>1#</sup> Rishab Gulati,<sup>1</sup> Yanal Ghosheh,<sup>1</sup> Christopher P. Durant,<sup>1</sup>  
4 Payel Roy,<sup>1</sup> Erik Ehinger,<sup>1</sup> Tanyapom Pattarabanjird,<sup>2</sup> Lindsey E. Padgett,<sup>1</sup> Claire E. Olingy,<sup>1</sup>  
5 David B. Hanna,<sup>3</sup> Alan L. Landay,<sup>4</sup> Russell P. Tracy,<sup>5</sup> Jason M. Lazar,<sup>6</sup> Wendy J. Mack,<sup>7,8</sup>  
6 Kathleen M. Weber,<sup>9</sup> Adaora A. Adimora,<sup>10</sup> Howard N. Hodis,<sup>7,8</sup> Phyllis C. Tien,<sup>11</sup> Igho Ofotokun,<sup>12</sup>  
7 Sonya L. Heath,<sup>13</sup> Huy Q. Dinh,<sup>1</sup> Avishai Shemesh,<sup>14</sup> Coleen A. McNamara,<sup>2</sup> Lewis L. Lanier,<sup>14</sup>  
8 Catherine C. Hedrick,<sup>1</sup> Robert C. Kaplan,<sup>3,15</sup> Klaus Ley.<sup>1,16\*</sup>

9

10 <sup>1</sup>La Jolla Institute for Immunology, La Jolla, CA, USA.

11 <sup>2</sup>Cardiovascular Research Center, Cardiovascular Division, Department of Medicine, University  
12 of Virginia, Charlottesville.

13 <sup>3</sup>Albert Einstein College of Medicine, Department of Epidemiology and Population Health, Bronx,  
14 NY, USA.

15 <sup>4</sup>Rush University Medical Center, Department of Internal Medicine, Chicago, IL, USA.

16 <sup>5</sup>University of Vermont Larner College of Medicine, Departments of Pathology & Laboratory  
17 Medicine and Biochemistry, Colchester, VT, USA.

18 <sup>6</sup>SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, USA.

19 <sup>7</sup>Keck School of Medicine, University of Southern California, Department of Preventive Medicine,  
20 Los Angeles, CA, USA.

21 <sup>8</sup>Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA, USA.

22 <sup>9</sup>Cook County Health/Hektoen Institute of Medicine, Chicago, IL, USA.

23 <sup>10</sup>Department of Medicine, University of North Carolina School of Medicine, The University of  
24 North Carolina at Chapel Hill, Chapel Hill, North Carolina.

1 <sup>11</sup>Department of Medicine, University of California, San Francisco, San Francisco, CA and  
2 Department of Veterans Affairs Medical Center, San Francisco, CA, USA.

3 <sup>12</sup>Emory University School of Medicine, Department of Medicine, Infectious Disease Division and  
4 Grady Health Care System, Atlanta, GA, USA.

5 <sup>13</sup>University of Alabama at Birmingham, Department of Medicine, Birmingham, AL, USA.

6 <sup>14</sup>Parker Institute for Cancer Immunotherapy, University of California, San Francisco, CA, USA;  
7 Department of Microbiology and Immunology, University of California, San Francisco, CA, USA.

8 <sup>15</sup> Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, USA.

9 <sup>16</sup> University of California San Diego, San Diego, CA, USA.

10

11

12

13

14

1 **Acknowledgements**

2

3 Supported by R35-HL-145241, R01-HL-121697, R01-HL-148094 to K.L., P01-KL-136275, R01-  
4 HL-134236 to C.C.H., R01-HL-126543, 5R01-HL-126543-05, 5R01-HL-140976-02, 1R01-HL-  
5 148094-01, R01-HL-148094 to R.C.K., K01-HL-137557 to D.B.H., U01-AI-103408 to I.O., U01-  
6 AI-103390 to A.A.A., U01-AI-034989 to P.C.T., Cancer Research Institute (CRI) to A.S., AHA-  
7 19POST34450020 to L.E.P, NIAID, NICHD, NCI, NIDA, NIMH, NIDCR, NIAAA, NIDCD, UL1-TR-  
8 000004, P30-AI-050409, P30-AI-050410, and P30-AI-027767. Data in this manuscript were  
9 collected by the Womens Interagency HIV study, now the MACS/WIHS Combined Cohort Study  
10 (MWCCS).

11

12 **Conflict of interest**

13

14 There are no conflicts of interest.

15

16 **Author contribution**

17

18 J.V., R.S., Y.G., C.P.D., E.E., and K.L. designed the study. A.L.L., R.P.T., J.M.L., W.J.M., K.M.W,  
19 A.A.A., H.N.H., P.C.T., I.O., S.L.H., and R.C.K., collected samples and data. D.B.H. analyzed  
20 clinical data. H.N.H. designed and collected data for the B mode ultrasound substudy. C.P.D.,  
21 and E.E. ran the scRNA-Seq experiments. J.V., R.S., R.G., Y.G., P.R., T.P., L.E.P., C.E.O.,  
22 H.Q.D., A.A., C.A.M., L.L.L., C.C.H., and K.L analyzed the data. R.G., Y.G. and H.Q.D. conducted  
23 the bioinformatics analysis. J.V., R.S., and K.L. wrote the manuscript.

24

25

26

## 1 References

- 2
- 3 1. Montaner JSG, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated  
4 with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV  
5 Treatment as Prevention” experience in a Canadian setting. *PLoS One*. 2014;9(2):e87872.  
6 doi:10.1371/journal.pone.0087872
- 7 2. Hanna DB, Lin J, Post WS, et al. Association of Macrophage Inflammation Biomarkers With  
8 Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men.  
9 *J Infect Dis*. 2017;215(9):1352-1361. doi:10.1093/infdis/jix082
- 10 3. Mocroft A, Reiss P, Gasiowski J, et al. Serious fatal and nonfatal non-AIDS-defining  
11 illnesses in Europe. *J Acquir Immune Defic Syndr*. 2010;55(2):262-270.  
12 doi:10.1097/QAI.0b013e3181e9be6b
- 13 4. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with  
14 nonfatal AIDS and serious non-AIDS events among adults infected with HIV. *AIDS*.  
15 2010;24(5):697-706. doi:10.1097/QAD.0b013e3283365356
- 16 5. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients  
17 treated for human immunodeficiency virus infection compared with the general population.  
18 *Clin Infect Dis*. 2003;37(2):292-298. doi:10.1086/375844
- 19 6. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk  
20 in HIV-infected men and women. *Clin Infect Dis*. 2007;45(8):1074-1081.  
21 doi:10.1086/521935
- 22 7. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing  
23 population infected with HIV: a modelling study. *Lancet Infect Dis*. 2015;15(7):810-818.  
24 doi:10.1016/S1473-3099(15)00056-0
- 25 8. Twigg HL 3rd, Crystal R, Currier J, et al. Refining Current Scientific Priorities and Identifying  
26 New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research. *AIDS Res*

- 1 *Hum Retroviruses*. 2017;33(9):889-897. doi:10.1089/AID.2017.0026
- 2 9. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. *Nat Rev Dis Prim*.  
3 2015;1:15035. doi:10.1038/nrdp.2015.35
- 4 10. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1  
5 antiretroviral therapy. *N Engl J Med*. 2013;368(3):218-230. doi:10.1056/NEJMoa1110187
- 6 11. Milush JM, Lopez-Verges S, York VA, et al. CD56negCD16(+) NK cells are activated  
7 mature NK cells with impaired effector function during HIV-1 infection. *Retrovirology*.  
8 2013;10:158. doi:10.1186/1742-4690-10-158
- 9 12. Mueller KAL, Hanna DB, Ehinger E, et al. Loss of CXCR4 on non-classical monocytes in  
10 participants of the Women's Interagency HIV Study (WIHS) with subclinical  
11 atherosclerosis. *Cardiovasc Res*. 2019;115(6):1029-1040. doi:10.1093/cvr/cvy292
- 12 13. Baker J V, Hullsiek KH, Singh A, et al. Immunologic predictors of coronary artery calcium  
13 progression in a contemporary HIV cohort. *AIDS*. 2014;28(6):831-840.  
14 doi:10.1097/QAD.0000000000000145
- 15 14. Schechter ME, Andrade BB, He T, et al. Inflammatory monocytes expressing tissue factor  
16 drive SIV and HIV coagulopathy. *Sci Transl Med*. 2017;9(405).  
17 doi:10.1126/scitranslmed.aam5441
- 18 15. Ehinger E, Ghosheh Y, Bala PA, et al. Classical Monocyte Transcriptomes Reveal  
19 Significant Anti- Inflammatory Statin Effect in Women with Chronic HIV. *Cardiovasc Res*.  
20 Forthcomin.
- 21 16. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets.  
22 *Trends Immunol*. 2001;22(11):633-640. doi:10.1016/s1471-4906(01)02060-9
- 23 17. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate  
24 immunoregulatory role for the CD56(bright) subset. *Blood*. 2001;97(10):3146-3151.  
25 doi:10.1182/blood.v97.10.3146
- 26 18. Jacobs R, Hintzen G, Kemper A, et al. CD56bright cells differ in their KIR repertoire and

- 1 cytotoxic features from CD56dim NK cells. *Eur J Immunol*. 2001;31(10):3121-3127.  
2 doi:10.1002/1521-4141(2001010)31:10<3121::aid-immu3121>3.0.co;2-4
- 3 19. Smith SL, Kennedy PR, Stacey KB, et al. Diversity of peripheral blood human NK cells  
4 identified by single-cell RNA sequencing. *Blood Adv*. 2020;4(7):1388-1406.  
5 doi:10.1182/bloodadvances.2019000699
- 6 20. Hu PF, Hultin LE, Hultin P, et al. Natural killer cell immunodeficiency in HIV disease is  
7 manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a  
8 population of CD16dimCD56- cells with low lytic activity. *J Acquir Immune Defic Syndr Hum*  
9 *Retrovirol*. 1995;10(3):331-340.
- 10 21. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer  
11 (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals.  
12 *Proc Natl Acad Sci U S A*. 2005;102(8):2886-2891. doi:10.1073/pnas.0409872102
- 13 22. Gonzalez VD, Falconer K, Michaelsson J, et al. Expansion of CD56- NK cells in chronic  
14 HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and  
15 ribavirin. *Clin Immunol*. 2008;128(1):46-56. doi:10.1016/j.clim.2008.03.521
- 16 23. Phillips AN, Sabin CA, Elford J, Bofill M, Lee CA, Janossy G. CD8 lymphocyte counts and  
17 serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte  
18 depletion during 8 years of follow-up. *AIDS*. 1993;7(7):975-980. doi:10.1097/00002030-  
19 199307000-00011
- 20 24. Badejo OA, Chang C-C, So-Armah KA, et al. CD8+ T-cells count in acute myocardial  
21 infarction in HIV disease in a predominantly male cohort. *Biomed Res Int*.  
22 2015;2015:246870. doi:10.1155/2015/246870
- 23 25. Overton ET, Sterrett S, Westfall AO, et al. Effects of atorvastatin and pravastatin on  
24 immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected  
25 patients. *AIDS*. 2014;28(17):2627-2631. doi:10.1097/QAD.0000000000000475
- 26 26. Eckard AR, Meissner EG, Singh I, McComsey GA. Cardiovascular Disease, Statins, and

- 1 HIV. *J Infect Dis.* 2016;214 Suppl(Suppl 2):S83-92. doi:10.1093/infdis/jiw288
- 2 27. Griffin DO, Rothstein TL. Human b1 cell frequency: isolation and analysis of human b1  
3 cells. *Front Immunol.* 2012;3:122. doi:10.3389/fimmu.2012.00122
- 4 28. Upadhye A, Srikakulapu P, Gonen A, et al. Diversification and CXCR4-Dependent  
5 Establishment of the Bone Marrow B-1a Cell Pool Governs Atheroprotective IgM  
6 Production Linked to Human Coronary Atherosclerosis. *Circ Res.* 2019;125(10):e55-e70.  
7 doi:10.1161/CIRCRESAHA.119.315786
- 8 29. Tanigawa T, Kitamura A, Yamagishi K, et al. Relationships of differential leukocyte and  
9 lymphocyte subpopulations with carotid atherosclerosis in elderly men. *J Clin Immunol.*  
10 2003;23(6):469-476. doi:10.1023/b:joci.0000010423.65719.e5
- 11 30. Moir S, Fauci AS. B-cell responses to HIV infection. *Immunol Rev.* 2017;275(1):33-48.  
12 doi:10.1111/imr.12502
- 13 31. Moir S, Fauci AS. B cells in HIV infection and disease. *Nat Rev Immunol.* 2009;9(4):235-  
14 245. doi:10.1038/nri2524
- 15 32. Karnell JL, Kumar V, Wang J, Wang S, Voynova E, Ettinger R. Role of CD11c(+) T-bet(+)  
16 B cells in human health and disease. *Cell Immunol.* 2017;321:40-45.  
17 doi:10.1016/j.cellimm.2017.05.008
- 18 33. Guillaumet-Adkins A, Rodriguez-Esteban G, Mereu E, et al. Single-cell transcriptome  
19 conservation in cryopreserved cells and tissues. *Genome Biol.* 2017;18(1):45.  
20 doi:10.1186/s13059-017-1171-9
- 21 34. Williams JW, Winkels H, Durant CP, Zaitsev K, Ghosheh Y, Ley K. Single Cell RNA  
22 Sequencing in Atherosclerosis. *Circ Res.* 2020;126(9):1112-1126.  
23 doi:10.1161/CIRCRESAHA.119.315940
- 24 35. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major  
25 atherosclerosis risk factor in HIV-infected women and men. *AIDS.* 2008;22(13):1615-1624.  
26 doi:10.1097/QAD.0b013e328300581d



- 1 36. Hanna DB, Post WS, Deal JA, et al. HIV Infection Is Associated With Progression of  
2 Subclinical Carotid Atherosclerosis. *Clin Infect Dis.* 2015;61(4):640-650.  
3 doi:10.1093/cid/civ325
- 4 37. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A  
5 randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 2001;135(11):939-953.  
6 doi:10.7326/0003-4819-135-11-200112040-00005
- 7 38. Zheng C, Zheng L, Yoo J-K, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed  
8 by Single-Cell Sequencing. *Cell.* 2017;169(7):1342-1356.e16.  
9 doi:10.1016/j.cell.2017.05.035
- 10 39. Zhang Y, Zheng L, Zhang L, Hu X, Ren X, Zhang Z. Deep single-cell RNA sequencing data  
11 of individual T cells from treatment-naive colorectal cancer patients. *Sci data.*  
12 2019;6(1):131. doi:10.1038/s41597-019-0131-5
- 13 40. Zhang L, Li Z, Skrzypczynska KM, et al. Single-Cell Analyses Inform Mechanisms of  
14 Myeloid-Targeted Therapies in Colon Cancer. *Cell.* 2020;181(2):442-459.e29.  
15 doi:10.1016/j.cell.2020.03.048
- 16 41. Brown CC, Gudjonson H, Pritykin Y, et al. Transcriptional Basis of Mouse and Human  
17 Dendritic Cell Heterogeneity. *Cell.* 2019;179(4):846-863.e24.  
18 doi:10.1016/j.cell.2019.09.035
- 19 42. Uniken Venema WT, Voskuil MD, Vila AV, et al. Single-Cell RNA Sequencing of Blood and  
20 Ileal T Cells From Patients With Crohn's Disease Reveals Tissue-Specific Characteristics  
21 and Drug Targets. *Gastroenterology.* 2019;156(3):812-815.e22.  
22 doi:10.1053/j.gastro.2018.10.046
- 23 43. Martin JC, Chang C, Boschetti G, et al. Single-Cell Analysis of Crohn's Disease Lesions  
24 Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy.  
25 *Cell.* 2019;178(6):1493-1508.e20. doi:10.1016/j.cell.2019.08.008
- 26 44. Reyes M, Vickers D, Billman K, et al. Multiplexed enrichment and genomic profiling of

- 1 peripheral blood cells reveal subset-specific immune signatures. *Sci Adv.*  
2 2019;5(1):eaau9223. doi:10.1126/sciadv.aau9223
- 3 45. Kotliarov Y, Sparks R, Martins AJ, et al. Broad immune activation underlies shared set  
4 point signatures for vaccine responsiveness in healthy individuals and disease activity in  
5 patients with lupus. *Nat Med.* 2020. doi:10.1038/s41591-020-0769-8
- 6 46. Kazer SW, Aicher TP, Muema DM, et al. Integrated single-cell analysis of multicellular  
7 immune dynamics during hyperacute HIV-1 infection. *Nat Med.* 2020;26(4):511-518.  
8 doi:10.1038/s41591-020-0799-2
- 9 47. Fan HC, Fu GK, Fodor SPA. Expression profiling. Combinatorial labeling of single cells for  
10 gene expression cytometry. *Science.* 2015;347(6222). doi:10.1126/science.1258367
- 11 48. Mair F, Erickson JR, Voillet V, et al. A Targeted Multi-omic Analysis Approach Measures  
12 Protein Expression and Low-Abundance Transcripts on the Single-Cell Level. *Cell Rep.*  
13 2020;31(1):107499. doi:10.1016/j.celrep.2020.03.063
- 14 49. Stoeckius M, Hafemeister C, Stephenson W, et al. Simultaneous epitope and  
15 transcriptome measurement in single cells. *Nat Methods.* 2017;14(9):865-868.  
16 doi:10.1038/nmeth.4380
- 17 50. Peterson VM, Zhang KX, Kumar N, et al. Multiplexed quantification of proteins and  
18 transcripts in single cells. *Nat Biotechnol.* 2017;35(10):936-939. doi:10.1038/nbt.3973
- 19 51. Biburger M, Trenkwald I, Nimmerjahn F. Three blocks are not enough--Blocking of the  
20 murine IgG receptor FcγRIV is crucial for proper characterization of cells by FACS analysis.  
21 *Eur J Immunol.* 2015;45(9):2694-2697. doi:10.1002/eji.201545463
- 22 52. Andersen MN, Al-Karradi SNH, Kragstrup TW, Hokland M. Elimination of erroneous results  
23 in flow cytometry caused by antibody binding to Fc receptors on human monocytes and  
24 macrophages. *Cytometry A.* 2016;89(11):1001-1009. doi:10.1002/cyto.a.22995
- 25 53. Ravetch J V, Clynes RA. Divergent roles for Fc receptors and complement in vivo. *Annu*  
26 *Rev Immunol.* 1998;16:421-432. doi:10.1146/annurev.immunol.16.1.421

- 1 54. Ravetch J V. Fc receptors. *Curr Opin Immunol*. 1997;9(1):121-125. doi:10.1016/s0952-  
2 7915(97)80168-9
- 3 55. Ravetch J V, Bolland S. IgG Fc receptors. *Annu Rev Immunol*. 2001;19:275-290.  
4 doi:10.1146/annurev.immunol.19.1.275
- 5 56. Nimmerjahn F, Ravetch J V. Fc-Receptors as Regulators of Immunity. *Adv Immunol*.  
6 2007;96:179-204. doi:10.1016/S0065-2776(07)96005-8
- 7 57. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic  
8 data across different conditions, technologies, and species. *Nat Biotechnol*.  
9 2018;36(5):411-420. doi:10.1038/nbt.4096
- 10 58. Stuart T, Butler A, Hoffman P, et al. Comprehensive Integration of Single-Cell Data. *Cell*.  
11 2019;177(7):1888-1902.e21. doi:10.1016/j.cell.2019.05.031
- 12 59. Winkels H, Ehinger E, Vassallo M, et al. Atlas of the immune cell repertoire in mouse  
13 atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. *Circ Res*.  
14 2018;122(12):1675-1688. doi:10.1161/CIRCRESAHA.117.312513
- 15 60. Cole JE, Park I, Ahern DJ, et al. Immune cell census in murine atherosclerosis: cytometry  
16 by time of flight illuminates vascular myeloid cell diversity. *Cardiovasc Res*.  
17 2018;114(10):1360-1371. doi:10.1093/cvr/cvy109
- 18 61. Spitzer MH, Nolan GP. Mass Cytometry: Single Cells, Many Features. *Cell*.  
19 2016;165(4):780-791. doi:10.1016/j.cell.2016.04.019
- 20 62. Robinson JP, Roederer M. HISTORY OF SCIENCE. Flow cytometry strikes gold. *Science*.  
21 2015;350(6262):739-740. doi:10.1126/science.aad6770
- 22 63. Liu Y, Beyer A, Aebersold R. On the Dependency of Cellular Protein Levels on mRNA  
23 Abundance. *Cell*. 2016;165(3):535-550. doi:10.1016/j.cell.2016.03.014
- 24 64. Lundberg E, Fagerberg L, Klevebring D, et al. Defining the transcriptome and proteome in  
25 three functionally different human cell lines. *Mol Syst Biol*. 2010;6:450.  
26 doi:10.1038/msb.2010.106

- 1 65. Cochain C, Vafadarnejad E, Arampatzi P, et al. Single-Cell RNA-Seq Reveals the  
2 Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine  
3 Atherosclerosis. *Circ Res.* 2018;122(12):1661-1674.  
4 doi:10.1161/CIRCRESAHA.117.312509
- 5 66. Ong S-M, Teng K, Newell E, et al. A Novel, Five-Marker Alternative to CD16-CD14 Gating  
6 to Identify the Three Human Monocyte Subsets. *Front Immunol.* 2019;10:1761.  
7 doi:10.3389/fimmu.2019.01761
- 8 67. Spear TT, Nishimura MI, Simms PE. Comparative exploration of multidimensional flow  
9 cytometry software: a model approach evaluating T cell polyfunctional behavior. *J Leukoc*  
10 *Biol.* 2017;102(2):551-561. doi:10.1189/jlb.6A0417-140R
- 11 68. Bryceson YT, Fauriat C, Nunes JM, et al. Functional analysis of human NK cells by flow  
12 cytometry. *Methods Mol Biol.* 2010;612:335-352. doi:10.1007/978-1-60761-362-6\_23
- 13 69. Hong HS, Eberhard JM, Keudel P, et al. Phenotypically and functionally distinct subsets  
14 contribute to the expansion of CD56-/CD16+ natural killer cells in HIV infection. *AIDS.*  
15 2010;24(12):1823-1834. doi:10.1097/QAD.0b013e32833b556f
- 16 70. Gregson JNS, Kuri-Cervantes L, Mela CM, Gazzard BG, Bower M, Goodier MR. Short  
17 communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV  
18 type 1+ individuals with high plasma viral load. *AIDS Res Hum Retroviruses.*  
19 2013;29(1):84-88. doi:10.1089/AID.2011.0397
- 20 71. Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid cells: partners in host  
21 defense. *Nat Immunol.* 2016;17(7):758-764. doi:10.1038/ni.3482
- 22 72. Subelj L, Bajec M. Unfolding communities in large complex networks: combining defensive  
23 and offensive label propagation for core extraction. *Phys Rev E Stat Nonlin Soft Matter*  
24 *Phys.* 2011;83(3 Pt 2):36103. doi:10.1103/PhysRevE.83.036103
- 25 73. Hartigan-O'Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells  
26 express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent

- 1 identification and sorting of live cells. *J Immunol Methods*. 2007;319(1-2):41-52.  
2 doi:10.1016/j.jim.2006.10.008
- 3 74. Staats J. Immunophenotyping of Human Regulatory T Cells. *Methods Mol Biol*.  
4 2019;2032:141-177. doi:10.1007/978-1-4939-9650-6\_9
- 5 75. Acosta-Rodriguez E V, Rivino L, Geginat J, et al. Surface phenotype and antigenic  
6 specificity of human interleukin 17-producing T helper memory cells. *Nat Immunol*.  
7 2007;8(6):639-646. doi:10.1038/ni1467
- 8 76. Emoto M, Zerrahn J, Miyamoto M, Perarnau B, Kaufmann SH. Phenotypic characterization  
9 of CD8(+)NKT cells. *Eur J Immunol*. 2000;30(8):2300-2311. doi:10.1002/1521-  
10 4141(2000)30:8<2300::AID-IMMU2300>3.0.CO;2-2
- 11 77. Seregin SS, Chen GY, Laouar Y. Dissecting CD8+ NKT Cell Responses to Listeria  
12 Infection Reveals a Component of Innate Resistance. *J Immunol*. 2015;195(3):1112-1120.  
13 doi:10.4049/jimmunol.1500084
- 14 78. Hamers AAJ, Dinh HQ, Thomas GD, et al. Human Monocyte Heterogeneity as Revealed  
15 by High-Dimensional Mass Cytometry. *Arterioscler Thromb Vasc Biol*. 2019;39(1):25-36.  
16 doi:10.1161/ATVBAHA.118.311022
- 17 79. SahBandar IN, Ndhlovu LC, Saiki K, et al. Relationship between Circulating Inflammatory  
18 Monocytes and Cardiovascular Disease Measures of Carotid Intimal Thickness. *J*  
19 *Atheroscler Thromb*. 2020;27(5):441-448. doi:10.5551/jat.49791
- 20 80. Ruiz-Limon P, Ortega-Castro R, Barbarroja N, et al. Molecular Characterization of  
21 Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With  
22 Cardiovascular Disease in Rheumatoid Arthritis. *Front Immunol*. 2019;10:1111.  
23 doi:10.3389/fimmu.2019.01111
- 24 81. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte  
25 subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell  
26 population. *Arthritis Rheum*. 2012;64(3):671-677. doi:10.1002/art.33418

- 1 82. Rogacev KS, Cremers B, Zawada AM, et al. CD14<sup>++</sup>CD16<sup>+</sup> monocytes independently  
2 predict cardiovascular events: a cohort study of 951 patients referred for elective coronary  
3 angiography. *J Am Coll Cardiol*. 2012;60(16):1512-1520. doi:10.1016/j.jacc.2012.07.019
- 4 83. Tsukamoto M, Seta N, Yoshimoto K, Suzuki K, Yamaoka K, Takeuchi T.  
5 CD14(bright)CD16<sup>+</sup> intermediate monocytes are induced by interleukin-10 and positively  
6 correlate with disease activity in rheumatoid arthritis. *Arthritis Res Ther*. 2017;19(1):28.  
7 doi:10.1186/s13075-016-1216-6
- 8 84. Han J, Wang B, Han N, et al. CD14(high)CD16(+) rather than CD14(low)CD16(+)  
9 monocytes correlate with disease progression in chronic HIV-infected patients. *J Acquir*  
10 *Immune Defic Syndr*. 2009;52(5):553-559. doi:10.1097/qai.0b013e3181c1d4fe
- 11 85. Ellery PJ, Tippet E, Chiu Y-L, et al. The CD16<sup>+</sup> monocyte subset is more permissive to  
12 infection and preferentially harbors HIV-1 in vivo. *J Immunol*. 2007;178(10):6581-6589.  
13 doi:10.4049/jimmunol.178.10.6581
- 14 86. Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GYH. The CD14<sup>++</sup>CD16<sup>+</sup> monocyte  
15 subset and monocyte-platelet interactions in patients with ST-elevation myocardial  
16 infarction. *J Thromb Haemost*. 2012;10(7):1231-1241. doi:10.1111/j.1538-  
17 7836.2011.04603.x
- 18 87. Wrigley BJ, Shantsila E, Tapp LD, Lip GYH. CD14<sup>++</sup>CD16<sup>+</sup> monocytes in patients with  
19 acute ischaemic heart failure. *Eur J Clin Invest*. 2013;43(2):121-130.  
20 doi:10.1111/eci.12023
- 21 88. Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical Monocytes in  
22 Health and Disease. *Annu Rev Immunol*. 2019;37:439-456. doi:10.1146/annurev-immunol-  
23 042617-053119
- 24 89. Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I. Advances in human B cell phenotypic  
25 profiling. *Front Immunol*. 2012;3:302. doi:10.3389/fimmu.2012.00302
- 26 90. Amu S, Tarkowski A, Dorner T, Bokarewa M, Brisslert M. The human immunomodulatory

- 1 CD25+ B cell population belongs to the memory B cell pool. *Scand J Immunol.*  
2 2007;66(1):77-86. doi:10.1111/j.1365-3083.2007.01946.x
- 3 91. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a  
4 dysfunctional memory B cell compartment in HIV-infected viremic individuals. *J Exp Med.*  
5 2008;205(8):1797-1805. doi:10.1084/jem.20072683
- 6 92. Krämer A, Green J, Pollard JJ, Tugendreich S. Causal analysis approaches in Ingenuity  
7 Pathway Analysis. *Bioinformatics.* 2014;30(4):523-530. doi:10.1093/bioinformatics/btt703
- 8 93. Nakayama M, Niki Y, Kawasaki T, et al. IL-32-PAR2 axis is an innate immunity sensor  
9 providing alternative signaling for LPS-TRIF axis. *Sci Rep.* 2013;3:2960.  
10 doi:10.1038/srep02960
- 11 94. Damen MSMA, Popa CD, Netea MG, Dinarello CA, Joosten LAB. Interleukin-32 in chronic  
12 inflammatory conditions is associated with a higher risk of cardiovascular diseases.  
13 *Atherosclerosis.* 2017;264:83-91. doi:10.1016/j.atherosclerosis.2017.07.005
- 14 95. Kim S-H, Han S-Y, Azam T, Yoon D-Y, Dinarello CA. Interleukin-32: a cytokine and inducer  
15 of TNFalpha. *Immunity.* 2005;22(1):131-142. doi:10.1016/j.immuni.2004.12.003
- 16 96. Virani SS, Nambi V, Hoogeveen R, et al. Relationship between circulating levels of  
17 RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid  
18 plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study.  
19 *Eur Heart J.* 2011;32(4):459-468. doi:10.1093/eurheartj/ehq367
- 20 97. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell  
21 survival. *Annu Rev Immunol.* 2003;21:231-264.  
22 doi:10.1146/annurev.immunol.21.120601.141152
- 23 98. Smulski CR, Eibel H. BAFF and BAFF-Receptor in B Cell Selection and Survival. *Front*  
24 *Immunol.* 2018;9:2285. doi:10.3389/fimmu.2018.02285
- 25 99. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for  
26 Atherosclerotic Disease. *N Engl J Med.* 2017;377(12):1119-1131.

- 1 doi:10.1056/NEJMoa1707914
- 2 100. Tobias PS, Curtiss LK. TLR2 in murine atherosclerosis. *Semin Immunopathol.*  
3 2008;30(1):23-27. doi:10.1007/s00281-007-0102-3
- 4 101. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like  
5 receptor 2. *J Clin Invest.* 2005;115(11):3149-3156. doi:10.1172/JCI25482
- 6 102. Mullick AE, Soldau K, Kiosses WB, Bell TA 3rd, Tobias PS, Curtiss LK. Increased  
7 endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates  
8 early atherogenic events. *J Exp Med.* 2008;205(2):373-383. doi:10.1084/jem.20071096
- 9 103. Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine  
10 is a ligand for HIV-coreceptor Bonzo. *Nat Immunol.* 2000;1(4):298-304. doi:10.1038/79738
- 11 104. Zhao G, Wang S, Wang Z, et al. CXCR6 deficiency ameliorated myocardial  
12 ischemia/reperfusion injury by inhibiting infiltration of monocytes and IFN- $\gamma$ -dependent  
13 autophagy. *Int J Cardiol.* 2013;168(2):853-862. doi:10.1016/j.ijcard.2012.10.022
- 14 105. Wang J-H, Su F, Wang S, et al. CXCR6 deficiency attenuates pressure overload-induced  
15 monocytes migration and cardiac fibrosis through downregulating TNF- $\alpha$ -dependent  
16 MMP9 pathway. *Int J Clin Exp Pathol.* 2014;7(10):6514-6523.
- 17 106. Bekele Y, Lakshmikanth T, Chen Y, et al. Mass cytometry identifies distinct CD4+ T cell  
18 clusters distinguishing HIV-1-infected patients according to antiretroviral therapy initiation.  
19 *JCI insight.* 2019;4(3). doi:10.1172/jci.insight.125442
- 20 107. Hearps AC, Maisa A, Cheng W-J, et al. HIV infection induces age-related changes to  
21 monocytes and innate immune activation in young men that persist despite combination  
22 antiretroviral therapy. *AIDS.* 2012;26(7):843-853. doi:10.1097/QAD.0b013e328351f756
- 23 108. Martin GE, Gouillou M, Hearps AC, et al. Age-associated changes in monocyte and innate  
24 immune activation markers occur more rapidly in HIV infected women. *PLoS One.*  
25 2013;8(1):e55279. doi:10.1371/journal.pone.0055279
- 26 109. Liang H, Xie Z, Shen T. Monocyte activation and cardiovascular disease in HIV infection.



- 1 *Cell Mol Immunol.* 2017;14(12):960-962. doi:10.1038/cmi.2017.109
- 2 110. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1  
3 infection and in uninfected subjects with acute coronary syndrome. *Blood.*  
4 2012;120(23):4599-4608. doi:10.1182/blood-2012-05-433946
- 5 111. Wildgruber M, Aschenbrenner T, Wendorff H, et al. The “Intermediate” CD14(++)CD16(+)  
6 monocyte subset increases in severe peripheral artery disease in humans. *Sci Rep.*  
7 2016;6:39483. doi:10.1038/srep39483
- 8 112. Heine GH, Ulrich C, Seibert E, et al. CD14(++)CD16+ monocytes but not total monocyte  
9 numbers predict cardiovascular events in dialysis patients. *Kidney Int.* 2008;73(5):622-629.  
10 doi:10.1038/sj.ki.5002744
- 11 113. Rasool ST, Tang H, Wu J, et al. Increased level of IL-32 during human immunodeficiency  
12 virus infection suppresses HIV replication. *Immunol Lett.* 2008;117(2):161-167.  
13 doi:10.1016/j.imlet.2008.01.007
- 14 114. Toribio M, Fitch K V, Stone L, et al. Assessing statin effects on cardiovascular pathways in  
15 HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized  
16 controlled trial. *EBioMedicine.* 2018;35:58-66. doi:10.1016/j.ebiom.2018.08.039
- 17 115. Longenecker CT, Sattar A, Gilkeson R, McComsey GA. Rosuvastatin slows progression of  
18 subclinical atherosclerosis in patients with treated HIV infection. *AIDS.* 2016;30(14):2195-  
19 2203. doi:10.1097/QAD.0000000000001167
- 20 116. Hoffmann U, Lu MT, Olalere D, et al. Rationale and design of the Mechanistic Substudy of  
21 the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of  
22 pitavastatin on coronary artery disease and inflammatory biomarkers. *Am Heart J.*  
23 2019;212:1-12. doi:10.1016/j.ahj.2019.02.011
- 24 117. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System.  
25 *Circ Res.* 2017;120(1):229-243. doi:10.1161/CIRCRESAHA.116.308537
- 26 118. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. *N Engl J Med.*

- 1 2012;366(4):321-329. doi:10.1056/NEJMoa1012848
- 2 119. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study.  
3 WIHS Collaborative Study Group. *Epidemiology*. 1998;9(2):117-125.
- 4 120. Olson NC, Doyle MF, Sitlani CM, et al. Associations of Innate and Adaptive Immune Cell  
5 Subsets With Incident Type 2 Diabetes Risk: The MESA Study. *J Clin Endocrinol Metab*.  
6 2020;105(3). doi:10.1210/clinem/dgaa036
- 7 121. Clift IC. Diagnostic Flow Cytometry and the AIDS Pandemic. *Lab Med*. 2015;46(3):e59-64.  
8 doi:10.1309/LMKHW2C86ZJDRTFE
- 9 122. De Milito A. B lymphocyte dysfunctions in HIV infection. *Curr HIV Res*. 2004;2(1):11-21.  
10 doi:10.2174/1570162043485068
- 11 123. Bonaccorsi I, Spinelli D, Cantoni C, et al. Symptomatic Carotid Atherosclerotic Plaques Are  
12 Associated With Increased Infiltration of Natural Killer (NK) Cells and Higher Serum Levels  
13 of NK Activating Receptor Ligands. *Front Immunol*. 2019;10:1503.  
14 doi:10.3389/fimmu.2019.01503
- 15 124. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq.  
16 *Bioinformatics*. 2009;25(9):1105-1111. doi:10.1093/bioinformatics/btp120
- 17 125. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. *Bioinformatics*.  
18 2012;28(16):2184-2185. doi:10.1093/bioinformatics/bts356
- 19 126. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential  
20 expression analysis of digital gene expression data. *Bioinformatics*. 2010;26(1):139-140.  
21 doi:10.1093/bioinformatics/btp616
- 22 127. Milush JM, Long BR, Snyder-Cappione JE, et al. Functionally distinct subsets of human  
23 NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4.  
24 *Blood*. 2009;114(23):4823-4831. doi:10.1182/blood-2009-04-216374

25

26

1 **Supplemental figure legends**

2

3 **Figure S1. Study design overview.** Three group comparisons (HIV effect, CVD effect and  
4 cholesterol lowering treatment effect) and main steps of analysis.

5

6 **Figure S2. Unbiased UMAP clustering.** All cells were clustered based on 462 genes and 40  
7 antibody markers using Seurat, revealing B cells, monocytes, DCs, NK and T cells (left). The  
8 monocytes and DCs were re-clustered showing 3 classical, 2 intermediate and 4 nonclassical  
9 monocyte clusters, 1 DC and 1 monocyte-DC cluster (right).

10

11 **Figure S3. Gating scheme (A) and biaxial dot plots (B-E) to identify major known cell types.**

12 PBMCs from 32 WIHS participants were hash-tagged and stained with 40 oligonucleotide-tagged  
13 mAbs (table S3). **(B) B cells** were defined as CD19+CD3- and T cells as CD19-CD3+. **(C) T cells**  
14 were identified as CD4 (CD4+CD8-) or CD8 (CD4-CD8+). **(D)** All CD19-CD3- cells were gated for  
15 CD14 and CD16, with CD14+CD16- cells being classical (CM) and CD14+CD16+ being  
16 intermediate (INT) monocytes. **(E)** The CD14-CD16+ cells from panel D contain NK cells, which  
17 were identified by CD56 and defined as CD56+CD14-CD20-CD123-CD206-. Most of the  
18 remaining CD56-CD16+ cells were nonclassical monocytes (NCM).

19

20 **Figure S4. Rainbow plots of cell surface phenotype not shown in Figure 2.** The expression

21 level of each of the 40 antibody markers was color-coded from dark blue (=0, not expressed) to  
22 red (highest expression, log2 scale, as per color bar in each panel). **(A) CD4 T cells, (B) CD8 T**  
23 **cells, (C) Monocytes (Classical monocytes; CM, Intermediate monocytes; INT, and**  
24 **Nonclassical monocytes; NCM), (D) B cells, (E) NK cells.**

25

1 **Figure S5. Antibody expression in all clusters.** Violin plots for each of the 58 PBMC clusters.  
2 **(A) CD4+ T cells** (total of 16 clusters), **(B) CD8+T cells** (total of 14 clusters), **(C) Classical**  
3 **monocytes** (total of 6 clusters), **(D) Intermediate monocytes** (total of 5 clusters), **(E)**  
4 **Nonclassical monocytes** (total of 3 clusters), **(F) B cells** (total of 6 clusters), **(G) NK cells** (total  
5 of 6 clusters).

6  
7 **Figure S6. Pathway analysis.** Ingenuity pathway analysis (IPA) was conducted on all clusters,  
8 filtered for the 21 pathways most relevant to HIV and CVD. Enrichment p values shown as a heat  
9 map from blue ( $P < 0.05$ ) to red ( $p < 10^{-10}$ ).

10

11 **Figure S7. Remaining volcano plots not shown in Figure 7.**

12

1 **Supplemental Excel tables**

2

3 **Supplemental Excel Table S1. The data underlying Figure 4. Full gene expression matrix.**

4 **(A)** Average gene expression per cell in all clusters. **(B)** Log2 normalized gene expression. **(C-I)**

5 Gene expression of each cell in each cell type, **(C)** CD4 T cells, **(D)** CD8 T cells, **(E)** Classical

6 monocytes (CM), **(F)** Intermediate monocytes (INT), **(G)** Nonclassical monocytes (NCM), **(H)** B

7 cells, **(I)** NK cells.

8

9 **Supplemental Excel Table S2. The data underlying Figure 5. Differentially expressed genes**

10 [HIV-CVD- vs HIV+CVD-, HIV-CVD+ vs HIV+CVD+, HIV+CVD+ vs HIV+CVD+Statin (cholesterol

11 lowering drugs)] compared in each cell cluster. First group (before the '+') against second group

12 (after the '+'). gene: gene name, p\_val: raw p value, avg\_logFC: average log2 fold change, pct.1:

13 the percentage of cells that express the gene in the first group, pct.2: the percentage of cells

14 where the gene is detected in the second group, p\_val\_adj: adjusted p-value, based on Bonferroni

15 correction using all genes in the dataset p value adjusted by Benjamini-Hochberg for multiple

16 comparisons.

17

18 **Supplemental Excel Table S3. The data underlying Figure 6. Significantly differentially**

19 **expressed genes** in each PBMC cluster among the 4 patient types [HIV-CVD-, HIV+CVD-,

20 HIV+CVD+, HIV+CVD+Statin+ (cholesterol lowering drugs)]

21

22

23